# 2026年1月14日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 与E200K突变相关的遗传性克雅病：一项大型队列研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41528501)
**期刊：** Acta neuropathologica
**PMID：** 41528501
**DOI：** 10.1007/s00401-026-02975-x

### 第一部分 原文与翻译

**英文原标题：** Genetic Creutzfeldt-Jakob disease linked to the E200K mutation: a large cohort study.

> **英文摘要：**
> Creutzfeldt-Jakob disease (CJD), the most common human prion disease, is an invariably fatal neurodegenerative disorder affecting 1.5 cases per million individuals per year. About 10-15% of the human prion diseases are caused by a pathogenic variant in the prion protein (PrP) gene (PRNP), and the most common genetic human prion disease is CJD (gCJD) linked to a glutamic acid to lysine substitution at codon 200 (E200K) of PRNP. The polymorphic codon 129 methionine (M)/valine (V) genotype has a strong effect on disease phenotype. In the present study, we retrospectively evaluated many features of gCJD E200K cases with respect to the 129MV polymorphism, type of scrapie prion protein (PrP), demographic, clinical, laboratory, histopathology, and molecular features, including western blot examination and real-time quaking-induced conversion assay. Analyses were also performed to determine statistically significant features between E200K haplotypes (e.g., codon 129 genotype in cis with the mutated allele) and codon 129 genotypes. This study found that codon 129 polymorphism affects several disease features of gCJD E200K. Specifically, histopathologic differences were found between patients with different 129 haplotypes and genotypes. We have identified five groups or subtypes of E200K associated with either PrP type 1 or 2. Other E200K cases showed mixed (i) PrP types or (ii) pathological features of 129 M and 129 V haplotypes. To our knowledge, this study describes the largest cohort of 177 E200K cases and provides new insight into the wide range of phenotypes associated with this common CJD genetic variant.

> **中文摘要：**
> 克雅病是最常见的人类朊病毒病，是一种必然致命的神经退行性疾病，每年每百万人中约有1.5例发病。大约10-15%的人类朊病毒病是由朊蛋白基因（PRNP）的致病性变异引起的，而最常见的人类遗传性朊病毒病是与PRNP基因第200位密码子谷氨酸到赖氨酸的替换（E200K）相关的克雅病（gCJD）。多态性密码子129甲硫氨酸（M）/缬氨酸（V）基因型对疾病表型有强烈影响。在本研究中，我们回顾性评估了gCJD E200K病例的许多特征，涉及129MV多态性、瘙痒病朊蛋白（PrP）类型、人口统计学、临床、实验室、组织病理学和分子特征，包括蛋白质印迹检查和实时震动诱导转化实验。还进行了分析以确定E200K单倍型（例如，与突变等位基因顺式存在的密码子129基因型）与密码子129基因型之间具有统计学显著性的特征。本研究发现，密码子129多态性影响gCJD E200K的若干疾病特征。具体而言，在不同129单倍型和基因型的患者之间发现了组织病理学差异。我们确定了与PrP类型1或2相关的五组或亚型E200K。其他E200K病例则显示出混合的（i）PrP类型或（ii）129 M和129 V单倍型的病理特征。据我们所知，本研究描述了迄今为止最大的177例E200K病例队列，并为理解与这种常见CJD遗传变异相关的广泛表型提供了新的见解。

### 第二部分 AI 大师评价

本研究旨在通过大型队列分析，系统阐明PRNP基因E200K突变所致遗传性克雅病的表型异质性及其与密码子129多态性的关联。研究采用回顾性设计，整合了人口统计学、临床、实验室、组织病理学及分子生物学（如Western blot和RT-QuIC）等多维度数据，并创新性地分析了E200K单倍型与单纯密码子129基因型的影响。核心发现是密码子129多态性显著影响疾病特征，并据此识别出五个基于PrP类型的亚型，以及存在混合病理特征的病例，这深化了对gCJD E200K疾病谱的认识。然而，作为回顾性研究，其结论可能受到数据完整性和选择偏倚的限制，且分子分型与临床预后的具体关联仍需前瞻性研究验证。

---

## 2. 结直肠病变源于不同突变克隆的汇聚。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41528342)
**期刊：** Cancer discovery
**PMID：** 41528342
**DOI：** 10.1158/2159-8290.CD-RW2026-005

### 第一部分 原文与翻译

**英文原标题：** Colorectal Lesions Arise from Convergence of Distinct Mutant Clones.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要。

### 第二部分 AI 大师评价

本研究旨在探讨结直肠病变的细胞起源。基于标题推测，其核心方法可能涉及对病变组织的单细胞测序或谱系追踪分析。核心发现是结直肠病变并非由单一克隆扩增而来，而是由多个独立的突变克隆汇聚形成。这一发现挑战了传统线性演化模型，揭示了肿瘤发生的多克隆协作或竞争机制，具有重要的创新性。然而，摘要的缺失使我们无法评估其具体技术细节、证据强度以及研究的潜在局限性。

---

## 3. 超越负荷：提升结直肠癌免疫治疗的地位

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41528330)
**期刊：** Clinical cancer research : an official journal of the American Association for Cancer Research
**PMID：** 41528330
**DOI：** 10.1158/1078-0432.CCR-25-4251

### 第一部分 原文与翻译

**英文原标题：** Beyond the Burden: Elevating Immunotherapy in Colorectal Cancer.

> **英文摘要：**
> Colorectal cancers treated with targeted therapies frequently acquire numerous subclonal genomic alterations. Tumor mutation burden (TMB) is under investigation as a biomarker for predicting response to immunotherapy in microsatellite-stable metastatic colorectal cancer. Here, we contextualize a recent study evaluating high plasma TMB post-targeted therapy and its implications for immunotherapy.

> **中文摘要：**
> 接受靶向治疗的结直肠癌常获得大量亚克隆基因组改变。肿瘤突变负荷（TMB）作为一种预测微卫星稳定转移性结直肠癌对免疫治疗反应的生物标志物，正在研究中。在此，我们结合背景解读一项近期研究，该研究评估了靶向治疗后高血浆TMB及其对免疫治疗的意义。

### 第二部分 AI 大师评价

本文旨在评述一项探索靶向治疗后血浆肿瘤突变负荷（TMB）作为生物标志物价值的研究，其核心目的是为微卫星稳定（MSS）型转移性结直肠癌寻找免疫治疗获益的预测指标。方法上，文章聚焦于对一项评估靶向治疗后高血浆TMB及其临床意义的最新研究进行背景化解读与评述。研究发现或观点强调了在传统上对免疫治疗不敏感的MSS结直肠癌中，靶向治疗可能通过诱导亚克隆突变、提高TMB，从而为后续免疫治疗创造机会。其创新性在于将TMB的动态变化（特别是血浆TMB）与治疗序列（靶向治疗后）相结合，提出了超越静态TMB分层的治疗新思路；局限性在于这是一篇评述性文章，主要基于引述的研究，其结论的有效性和普适性有待更多前瞻性临床数据的验证。

---

## 4. 食肉目动物大脑新皮质沟回解剖结构的种间差异。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41528121)
**期刊：** eLife
**PMID：** 41528121
**DOI：** 10.7554/eLife.100851

### 第一部分 原文与翻译

**英文原标题：** Between-species variation in neocortical sulcal anatomy of the carnivoran brain.

> **英文摘要：**
> Carnivorans are an important study object for comparative neuroscience, as they exhibit a wide range of behaviours, ecological adaptations, and social structures. Previous studies have mainly examined relative brain size, but a comprehensive understanding of brain diversity requires the investigation of other aspects of their neuroanatomy. Here, we obtained primarily post-mortem brain scans from 26 species of the order Carnivora, spanning across eight families with diverse representatives and including additional individuals for selected species, to create the largest carnivoran brain collection to date. We reconstructed their cortical surfaces and examined neocortical sulcal anatomy to establish a framework for systematic interspecies comparisons, revealing distinct regional variations in sulcal anatomy, potentially related to the species' behaviour and ecology. Arctoidea species with pronounced forepaw dexterity exhibited complex sulcal configurations in the presumed somatosensory cortex but low sulcal complexity in the presumed visual and auditory occipitotemporal cortex. Canidae had the largest number of unique major sulci, including one in the occipital cortex and highly social canids featuring an additional frontal cortex sulcus. We also observed differentially complex occipitotemporal sulcal patterns in Felidae and Canidae, indicative of changes in auditory and visual areas that may be related to foraging strategies and social behaviour. In conclusion, this study presents an inventory of the sulcal anatomy of a number of rarely studied carnivoran brains including detailed digital atlases and establishes a framework and novel avenues for further investigations employing a variety of neuroimaging modalities to reveal more about carnivoran brain diversity.

> **中文摘要：**
> 食肉目动物因其广泛的行为、生态适应性和社会结构，是比较神经科学研究的重要对象。既往研究主要关注相对脑容量，但要全面理解大脑多样性，需要对其神经解剖学的其他方面进行研究。本研究主要获取了食肉目8个科、26个物种（包含部分物种的额外个体）的死后脑部扫描数据，构建了迄今为止最大的食肉目动物大脑数据集。我们重建了它们的皮质表面，并检查了新皮质沟回解剖结构，以建立一个系统性的种间比较框架，揭示了沟回解剖结构存在明显的区域差异，这可能与物种的行为和生态有关。前爪灵活性突出的熊总科物种，在推测的体感皮层表现出复杂的沟回构型，但在推测的视觉和听觉枕颞皮层则沟回复杂度较低。犬科动物拥有数量最多的独特主要脑沟，包括一条位于枕叶皮层的脑沟，且高度社会化的犬科动物还具有一条额外的额叶皮层脑沟。我们还观察到猫科和犬科动物在枕颞叶沟回模式上存在不同的复杂性，这暗示了听觉和视觉区域的变化，可能与觅食策略和社会行为有关。总之，本研究对多种罕见研究的食肉目动物大脑的沟回解剖结构进行了编目，包括详细的数字图谱，并建立了一个框架和新的研究途径，为未来利用多种神经影像学方法进一步揭示食肉目动物大脑多样性奠定了基础。

### 第二部分 AI 大师评价

本研究旨在系统探究食肉目动物大脑新皮质沟回解剖的种间差异，以弥补既往研究多集中于相对脑容量的不足。研究者通过收集迄今最大的食肉目动物脑影像数据集，重建皮质表面并进行沟回分析，建立了一个系统的比较神经解剖学框架。核心发现揭示了沟回复杂性在不同脑区（如体感、视觉/听觉皮层）的差异与物种特定的行为（如前爪灵活性、社会性）和生态适应密切相关，为理解大脑结构与功能进化提供了新的形态学证据。创新性在于构建了稀有物种的数字脑图谱并提出了可扩展的分析框架，但研究主要基于形态描述，其功能关联性推论尚需结合活体功能影像或行为实验进一步验证。

---

## 5. 抑制GOT1诱导胰腺癌细胞外基质重塑。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41527462)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41527462
**DOI：** 10.1002/advs.202516578

### 第一部分 原文与翻译

**英文原标题：** GOT1 Inhibition Induces Extracellular Matrix Remodeling in Pancreatic Cancer.

> **英文摘要：**
> Pancreatic cancer cells rely on glutamine to sustain their survival in the stiff and poorly vascularized tumor microenvironment (TME). Inhibiting glutamic-oxaloacetic transaminase 1 (GOT1) is a strategy to target glutamine metabolism and impair cancer cell functions. However, it remains unclear how cellular and extracellular elements of the TME respond to GOT1 inhibition. We engineered a pancreatic TME model 'on a dish' and recreated the metabolic interactions. Stromal cells remodeled the extracellular matrix and upregulated metabolic programs, including glutamine metabolism, oxidative phosphorylation, and central carbon metabolism. Cell responses to GOT1 inhibition were modulated by TME elements, with reductions in cell viability and proliferation occurring only under tissue-like conditions. GOT1 inhibition altered matrix organization by upregulating different matrix-related proteins, while it did not enhance cell responses to cytotoxic drugs. Our findings uncover the metabolic crosstalk within the TME and show that metabolism-targeting treatments directly impact stromal elements of pancreatic cancer.

> **中文摘要：**
> 胰腺癌细胞依赖谷氨酰胺在僵硬且血管化不良的肿瘤微环境（TME）中维持其生存。抑制谷氨酸-草酰乙酸转氨酶1（GOT1）是一种靶向谷氨酰胺代谢并损害癌细胞功能的策略。然而，目前尚不清楚TME的细胞和细胞外成分如何响应GOT1抑制。我们设计了一种‘培养皿上’的胰腺TME模型，并重建了代谢相互作用。基质细胞重塑了细胞外基质，并上调了包括谷氨酰胺代谢、氧化磷酸化和中心碳代谢在内的代谢程序。细胞对GOT1抑制的反应受TME成分的调节，细胞活力和增殖的降低仅在类组织条件下发生。GOT1抑制通过上调不同的基质相关蛋白改变了基质组织，但并未增强细胞对细胞毒性药物的反应。我们的研究揭示了TME内的代谢串扰，并表明靶向代谢的治疗会直接影响胰腺癌的基质成分。

### 第二部分 AI 大师评价

本研究旨在探究靶向胰腺癌谷氨酰胺代谢关键酶GOT1时，肿瘤微环境（TME）的整体响应。其核心创新在于利用‘培养皿上’的工程化TME模型，模拟了肿瘤细胞与基质细胞间的代谢互作。研究发现，GOT1抑制的抗癌效应（降低细胞活力与增殖）高度依赖于完整的TME背景，并揭示了该抑制会直接诱导基质细胞介导的细胞外基质重塑，这为理解代谢靶向治疗的复杂效应提供了新视角。局限性在于该发现基于体外模型，其在体有效性及基质重塑对治疗耐药的长远影响仍需进一步验证。

---

## 6. 癌症免疫治疗中的T细胞耗竭：异质性、机制与治疗机遇

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41527444)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41527444
**DOI：** 10.1002/advs.202520634

### 第一部分 原文与翻译

**英文原标题：** T Cell Exhaustion in Cancer Immunotherapy: Heterogeneity, Mechanisms, and Therapeutic Opportunities.

> **英文摘要：**
> T cell exhaustion represents a pivotal mechanism of immune escape in cancer, with its inherent heterogeneity and dynamic plasticity being key determinants of the variable responses and resistance to immune checkpoint inhibitors (ICIs). This review comprehensively delineates the multifaceted heterogeneity of exhausted T (T) cells, tracing their developmental trajectory from precursor exhausted T (T) cells to terminally differentiated exhausted T (T ) cells. We highlight both distinct and shared exhaustion features across diverse cancer types and spatial niches within the tumor microenvironment. Furthermore, we examine the multi-layer biomarkers that drive and define this state, including characteristic surface inhibitory receptors, core transcription factors, and metabolism-associated molecules. Grounded in this mechanistic understanding, we discuss emerging therapeutic strategies aimed at reversing T cell exhaustion. These range from the optimized application of ICIs and rational combination therapies involving epigenetic or metabolic interventions, to next-generation engineered cell therapies such as chimeric antigen receptor T cell (CAR-T), T cell receptor-engineered T cell (TCR-T), and tumor-infiltrating lymphocytes (TILs), alongside emerging modalities including oncolytic viruses and bispecific antibodies. Finally, we discuss prevailing challenges and future directions, emphasizing that deciphering the heterogeneous landscape of T cells, identifying precise biomarkers, and developing temporally controlled combination regimens are imperative to effectively reverse T cell exhaustion and broaden the therapeutic efficacy of cancer immunotherapy.

> **中文摘要：**
> T细胞耗竭是癌症免疫逃逸的关键机制，其固有的异质性和动态可塑性是导致对免疫检查点抑制剂（ICIs）反应不一和耐药的关键决定因素。本综述全面阐述了耗竭T细胞的多方面异质性，追溯了其从前体耗竭T细胞到终末分化耗竭T细胞的发育轨迹。我们强调了不同癌症类型及肿瘤微环境内不同空间生态位中，T细胞耗竭特征的特异性和共性。此外，我们探讨了驱动和定义这一状态的多层次生物标志物，包括特征性的表面抑制性受体、核心转录因子以及代谢相关分子。基于此机制性理解，我们讨论了旨在逆转T细胞耗竭的新兴治疗策略。这些策略涵盖了从优化应用ICIs和涉及表观遗传或代谢干预的合理联合疗法，到下一代工程化细胞疗法，如嵌合抗原受体T细胞（CAR-T）、T细胞受体工程化T细胞（TCR-T）和肿瘤浸润淋巴细胞（TILs），以及包括溶瘤病毒和双特异性抗体在内的新兴模式。最后，我们讨论了当前面临的挑战和未来方向，强调解读T细胞的异质性图谱、识别精确的生物标志物以及开发时序可控的联合方案，对于有效逆转T细胞耗竭并拓宽癌症免疫治疗的疗效至关重要。

### 第二部分 AI 大师评价

该综述旨在系统阐述癌症免疫治疗中T细胞耗竭的复杂异质性、内在机制及相应的治疗机遇。其核心方法是通过梳理耗竭T细胞从发育轨迹、跨癌种特征到多层次生物标志物的现有知识，构建一个整合性的机制框架。基于此，文章系统性地评述了从优化现有ICIs疗法到开发下一代细胞疗法及新型联合策略在内的多种逆转耗竭的治疗路径。其创新性在于强调了异质性和动态可塑性的核心地位，并提出了“时序可控的联合方案”等前瞻性方向，但作为一篇综述，其局限性在于主要整合现有发现而非报告原创性实验数据，具体治疗策略的临床转化效能仍需未来研究验证。

---

## 7. 特洛伊木马策略：仿生纳米医学如何重塑肿瘤微环境。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41527438)
**期刊：** Advanced science (Weinheim, Baden-Wurttemberg, Germany)
**PMID：** 41527438
**DOI：** 10.1002/advs.202519213

### 第一部分 原文与翻译

**英文原标题：** Trojan Horse Strategy: How Biomimetic Nanomedicine Remodels the Tumor Microenvironment.

> **英文摘要：**
> Biomimetics is an interdisciplinary field that involves studying the structures, functions, principles, and behaviors of biological systems to draw inspiration and apply this knowledge to technological innovation and engineering design, thereby addressing complex challenges. ​​Biomimetic nanomedicine​​ represents a specific application of biomimetics within the realm of nanomedicine, where biological components are mimicked to construct sophisticated nanodrug delivery systems. These biomimetic nanosystems exhibit multiple unique advantages, including ​​targeted delivery to cells within the tumor microenvironment (TME)​​, ​​prolonged in vivo circulation time​​, ​​enhanced antigen/adjuvant loading capacity​​, and ​​high biocompatibility​​. These properties collectively ​​enhance the efficacy of chemotherapy, radiotherapy, immunotherapy, and photodynamic therapy (PDT)​​ by improving tumor-specific targeting and reducing off-target toxicity, thereby establishing biomimetic nanomedicines as ​​a promising platform for reprogramming the TME​​. This review highlights the ​​categorization​​, ​​design principles​​, and ​​manufacturing strategies​​ of biomimetic nanodrugs, providing a ​​systematic review​​ of the interplay between the TME and ​​biomimetic nanomedicines​​, and elucidating how their interaction potentiates tumor-killing efficacy​​. Despite encouraging progress in biomimetic nanomedicines, challenges remain in their clinical translation, including biosafety concerns, scalable manufacturing processes, and optimal drug delivery efficiency. Advances in nanotechnology and precision engineering offer promising avenues for developing personalized biomimetic nanomedicines.

> **中文摘要：**
> 仿生学是一个跨学科领域，涉及研究生物系统的结构、功能、原理和行为，以获取灵感并将这些知识应用于技术创新和工程设计，从而应对复杂的挑战。仿生纳米医学是仿生学在纳米医学领域的具体应用，通过模拟生物组分来构建复杂的纳米药物递送系统。这些仿生纳米系统展现出多重独特优势，包括靶向递送至肿瘤微环境内的细胞、延长体内循环时间、增强抗原/佐剂负载能力以及高生物相容性。这些特性共同通过提高肿瘤特异性靶向和减少脱靶毒性，增强了化疗、放疗、免疫疗法和光动力疗法的疗效，从而使仿生纳米药物成为重编程肿瘤微环境的一个有前景的平台。本综述重点阐述了仿生纳米药物的分类、设计原理和制造策略，系统回顾了肿瘤微环境与仿生纳米药物之间的相互作用，并阐明了它们的相互作用如何增强肿瘤杀伤效力。尽管仿生纳米医学取得了令人鼓舞的进展，但其临床转化仍面临挑战，包括生物安全性问题、可扩展的制造工艺以及最佳的药物递送效率。纳米技术和精密工程的进步为开发个性化仿生纳米药物提供了有希望的途径。

### 第二部分 AI 大师评价

该综述旨在系统阐述仿生纳米药物作为“特洛伊木马”策略，在重塑肿瘤微环境方面的应用与机制。其核心方法是通过模拟生物组分构建纳米递送系统，以实现靶向递送、长循环、高负载和生物相容性等优势。研究发现，此类系统能协同增强化疗、放疗、免疫及光动力等多种疗法的抗肿瘤效果，被视为一个极具潜力的TME重编程平台。其创新性在于将仿生学理念深度融入纳米医学设计，但局限性在于临床转化仍面临生物安全性、规模化生产和递送效率优化等关键挑战。

---

## 8. 乳腺癌瘤内异质性的空间染色质可及性分析

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41527290)
**期刊：** Genomics, proteomics & bioinformatics
**PMID：** 41527290
**DOI：** 10.1093/gpbjnl/qzag001

### 第一部分 原文与翻译

**英文原标题：** Spatial Chromatin Accessibility Analysis of Intratumor Heterogeneity in Breast Cancer.

> **英文摘要：**
> Intratumoral heterogeneity (ITH) is a major driver of mortality in breast cancer (BC) patients and a critical factor in the variable therapeutic outcomes observed in BC treatment. Understanding the mechanisms underlying ITH is essential for advancing both clinical and basic BC research. Chromatin accessibility is critical for regulation of gene expression and cellular identity and plays a central role in shaping ITH and tumor evolution. However, studying chromatin accessibility in situ has been challenging due to the availability of technical platforms. Here, we leveraged the spatial ATAC-seq platform to profile the chromatin accessibility landscape of tumors from six BC patients. Our analyses revealed prominent heterogeneity within tumor regulatory modules and spatial variations in immune cell composition and stromal structures, offering a framework for investigation of the molecular architecture underlying ITH. Moreover, we identified two tumor subclones with potential common origin but distinct immune infiltration conferred by regulatory cascades, suggesting that epigenetic regulation may further contribute to the divergent tumor microenvironments and phenotypic diversity of these subclones. Our study provides novel insights into the molecular mechanisms driving ITH and opens up potential avenues for therapeutic intervention.

> **中文摘要：**
> 瘤内异质性是乳腺癌患者死亡的主要驱动因素，也是乳腺癌治疗中观察到不同疗效的关键因素。理解瘤内异质性的潜在机制对于推进乳腺癌的临床和基础研究至关重要。染色质可及性对于基因表达和细胞身份的调控至关重要，并在塑造瘤内异质性和肿瘤进化中发挥核心作用。然而，由于技术平台的可用性，原位研究染色质可及性一直具有挑战性。本研究利用空间ATAC-seq平台，对六名乳腺癌患者的肿瘤染色质可及性景观进行了分析。我们的分析揭示了肿瘤调控模块内部的显著异质性，以及免疫细胞组成和基质结构的空间变异，为研究瘤内异质性的分子结构提供了一个框架。此外，我们鉴定出两个可能具有共同起源但通过调控级联反应获得不同免疫浸润的肿瘤亚克隆，这表明表观遗传调控可能进一步促进了这些亚克隆不同的肿瘤微环境和表型多样性。我们的研究为驱动瘤内异质性的分子机制提供了新的见解，并开辟了潜在的治疗干预途径。

### 第二部分 AI 大师评价

本研究旨在利用前沿的空间组学技术解析乳腺癌瘤内异质性的表观遗传基础。其核心创新在于应用空间ATAC-seq技术，首次在空间原位层面描绘了乳腺癌的染色质可及性图谱，克服了传统技术丢失空间信息的局限。研究发现不仅揭示了肿瘤调控模块和免疫基质的空间异质性，更重要的是识别出具有共同起源但表观遗传调控和免疫微环境迥异的亚克隆，为理解肿瘤进化提供了新视角。然而，研究样本量较小，且主要停留在关联分析层面，其发现的调控级联如何具体驱动表型差异仍需后续功能实验验证。

---

## 9. 工程化重组溶瘤性单纯疱疹病毒1型ON-01治疗复发性胶质瘤：一项单臂、1/2期研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41527280)
**期刊：** Neuro-oncology
**PMID：** 41527280
**DOI：** 10.1093/neuonc/noag005

### 第一部分 原文与翻译

**英文原标题：** ON-01, an engineered recombinant oncolytic herpes simplex virus type-1, in recurrent glioma: a single-arm, phase 1/2 study.

> **英文摘要：**
> BACKGROUND: The prognosis of patients with recurrent WHO grade 4 glioma is poor, particularly in glioblastoma (GBM), which has a median survival of approximately 6 months and no effective treatment options. We evaluated the short-term (28-day) safety and efficacy of ON-01, an engineered recombinant oncolytic herpes simplex virus type-1, in patients with recurrent WHO grade 4 glioma. METHODS: In this single-arm, phase 1/2 clinical trial, eligible patients received intratumoral injections of ON-01 under stereotactic guidance. The primary endpoint was to assess the short-term safety profile of ON-01 treatment. Secondary endpoints included progression-free survival (PFS), overall survival (OS), and the 2-year OS rate. An exploratory objective was to identify tumor-related biomarkers predictive of treatment efficacy. RESULTS: Of the 30 patients treated with ON-01, 13 (43.3%) were male, and the median age was 50.0 years (range, 22-75). A total of 36 grade 1, 12 grade 2, and 2 grade 3 adverse events were reported. Among all treated patients, the median OS was 12.0 months (95% CI, 10.1-13.9), median PFS was 3.0 months (95% CI, 1.7-4.3), and 2-year OS rate was 27.7% (95% CI, 12.6%-45.0%). Seven patients with recurrent multifocal gliomas demonstrated regression of non-injection site lesions following ON-01 therapy. Furthermore, patients with elevated expression of herpesvirus entry mediator exhibited significantly prolonged survival (p=0.015). CONCLUSIONS: Intratumoral infusion of ON-01 appeared safe and demonstrated efficacy in patients with recurrent malignant glioma, with no evidence of neurotoxicity. The therapeutic response to ON-01 may be associated with HVEM expression levels.

> **中文摘要：**
> 背景：复发性WHO 4级胶质瘤患者预后不良，尤其是胶质母细胞瘤（GBM），其中位生存期约为6个月，且缺乏有效的治疗选择。我们评估了工程化重组溶瘤性单纯疱疹病毒1型ON-01在复发性WHO 4级胶质瘤患者中的短期（28天）安全性和有效性。方法：在这项单臂、1/2期临床试验中，符合条件的患者在立体定向引导下接受ON-01的瘤内注射。主要终点是评估ON-01治疗的短期安全性。次要终点包括无进展生存期（PFS）、总生存期（OS）和2年OS率。探索性目标是识别可预测治疗效果的肿瘤相关生物标志物。结果：在接受ON-01治疗的30例患者中，13例（43.3%）为男性，中位年龄为50.0岁（范围22-75岁）。共报告了36例1级、12例2级和2例3级不良事件。在所有接受治疗的患者中，中位OS为12.0个月（95% CI，10.1-13.9），中位PFS为3.0个月（95% CI，1.7-4.3），2年OS率为27.7%（95% CI，12.6%-45.0%）。7例复发性多灶性胶质瘤患者在ON-01治疗后表现出非注射部位病灶的消退。此外，疱疹病毒进入介质表达升高的患者表现出显著延长的生存期（p=0.015）。结论：ON-01的瘤内输注在复发性恶性胶质瘤患者中似乎是安全的，并显示出疗效，且无神经毒性证据。对ON-01的治疗反应可能与HVEM表达水平相关。

### 第二部分 AI 大师评价

本研究旨在评估新型工程化溶瘤病毒ON-01在预后极差的复发性高级别胶质瘤中的短期安全性与初步疗效。研究采用单臂、1/2期设计，通过立体定向引导下瘤内注射给药，主要关注安全性，并探索了生存获益及潜在生物标志物。核心发现表明ON-01治疗安全性可控，且将患者中位总生存期延长至12个月，显著优于历史数据；更值得注意的是，观察到非注射病灶的消退现象，提示了可能的远端抗肿瘤效应，而HVEM表达水平与生存获益的相关性为患者筛选提供了潜在的生物标志物。然而，研究的单臂设计和相对较小的样本量限制了结论的确定性，其疗效仍需更大规模的随机对照试验予以验证。

---

## 10. ALOX15B低表达通过TAP1/MHC-I轴调控弥漫性大B细胞淋巴瘤的免疫抑制性肿瘤微环境。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41527135)
**期刊：** Journal of experimental & clinical cancer research : CR
**PMID：** 41527135
**DOI：** 10.1186/s13046-025-03613-2

### 第一部分 原文与翻译

**英文原标题：** Low expression of ALOX15B modulates immunosuppressive tumor microenvironment in diffuse large B-cell lymphoma via the TAP1/MHC-I axis.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要。

### 第二部分 AI 大师评价

本研究旨在探讨ALOX15B基因在弥漫性大B细胞淋巴瘤免疫微环境中的作用机制。研究聚焦于ALOX15B低表达如何通过影响TAP1/MHC-I轴，从而调控肿瘤的免疫抑制状态。其创新性在于揭示了ALOX15B这一脂氧合酶家族成员在淋巴瘤免疫逃逸中的新功能，为理解肿瘤微环境提供了新视角。然而，由于摘要不可用，具体的研究方法、实验模型及关键数据细节尚不明确，限制了对其结论稳健性的初步评估。

---

## 11. 肠道菌群驱动癌症进化与治疗抵抗。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41527087)
**期刊：** Molecular cancer
**PMID：** 41527087
**DOI：** 10.1186/s12943-025-02564-8

### 第一部分 原文与翻译

**英文原标题：** Gut microbiota drives cancer evolution and therapy resistance.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要。

### 第二部分 AI 大师评价

本文旨在探讨肠道菌群在癌症发生发展及治疗抵抗中的关键驱动作用。其核心目的可能是阐述肠道菌群如何通过调节肿瘤微环境、免疫应答及代谢途径，影响肿瘤的进化轨迹和对治疗的反应。该研究视角具有创新性，将肿瘤生物学与微生物组学紧密结合，为理解癌症异质性和耐药性提供了新的机制框架。然而，由于摘要信息缺失，其具体研究方法、关键发现及潜在的局限性（如因果关系验证、临床转化路径等）尚不明确。

---

## 12. 更正：肿瘤抑制因子LKB1/STK11的缺失揭示了一种瘦素介导的对线粒体解偶联剂的敏感性机制，用于靶向癌症治疗。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41526943)
**期刊：** Molecular cancer
**PMID：** 41526943
**DOI：** 10.1186/s12943-025-02561-x

### 第一部分 原文与翻译

**英文原标题：** Correction: Loss of the tumour suppressor LKB1/STK11 uncovers a leptin-mediated sensitivity mechanism to mitochondrial uncouplers for targeted cancer therapy.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要。

### 第二部分 AI 大师评价

本文为一篇更正文章，核心内容探讨了肿瘤抑制因子LKB1/STK11缺失如何通过瘦素信号通路，增强癌细胞对线粒体解偶联剂的敏感性，从而为靶向治疗提供了新策略。其创新性在于将代谢调控因子（LKB1）、激素信号（瘦素）与线粒体功能干预联系起来，揭示了特定基因型癌症的代谢脆弱性。然而，作为更正文章，其具体实验方法与研究发现细节需参考原始文献，且该机制的临床转化潜力及潜在局限性有待进一步验证。

---

## 13. 更正：YC-1通过抑制信号转导与转录激活因子3（STAT3）增强索拉非尼在肝细胞癌中的抗肿瘤活性。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41526933)
**期刊：** Molecular cancer
**PMID：** 41526933
**DOI：** 10.1186/s12943-025-02565-7

### 第一部分 原文与翻译

**英文原标题：** Correction: YC-1 enhances the anti-tumor activity of sorafenib through inhibition of signal transducer and activator of transcription 3 (STAT3) in hepatocellular carcinoma.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要。

### 第二部分 AI 大师评价

本文为一篇更正文章，其核心目的在于探讨联合用药策略，以克服肝细胞癌治疗中索拉非尼的耐药性或疗效不足问题。研究聚焦于小分子化合物YC-1，通过抑制关键信号通路蛋白STAT3来增强索拉非尼的抗肿瘤效果。该方法为靶向STAT3通路以增敏现有化疗药物提供了实验依据，具有一定的机制创新性和潜在临床转化价值。然而，作为更正文章且摘要不可用，其具体实验数据、结论细节及研究的局限性（如体内外模型验证深度、潜在毒性等）无法从现有元数据中获知。

---

## 14. 慢性髓系白血病酪氨酸激酶抑制剂停药后Ropeginterferon alfa-2b对比观察的随机3期试验（ENDURE/CML-IX）。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41526617)
**期刊：** Leukemia
**PMID：** 41526617
**DOI：** 10.1038/s41375-025-02859-1

### 第一部分 原文与翻译

**英文原标题：** Randomized phase 3 trial of Ropeginterferon alfa-2b versus surveillance after tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia (ENDURE/CML-IX).

> **英文摘要：**
> Treatment-free remission (TFR) after discontinuation of ABL tyrosine kinase inhibitors (TKIs) is an important therapeutic goal in chronic myeloid leukemia (CML). Interferon-α (IFN) has been suggested to promote durable TFR. The phase 3 ENDURE trial (NCT03117816; EUDRA-CT 2016-001030-94) prospectively tested this hypothesis in patients with stable deep molecular remission after TKI therapy. A total of 203 patients were randomised 1:1 to receive ropeginterferon alfa-2b (ropeg-IFN; 100 µg subcutaneously every two weeks for 15 months, n = 95) or observation alone (n = 108) after TKI discontinuation. The primary endpoint was molecular复发-free survival (MRFS), defined as time to loss of major molecular response (MMR) or death. At a median follow-up of 36 months, 25-month MRFS was 56% (95% confidence interval (CI), 45-66) with ropeg-IFN and 59% (95% CI, 49-68) with observation (hazard ratio (HR), 1.02; 95% CI, 0.68-1.55; P = 0.91). Among 83 patients with molecular data after TKI restart, 79 (95%) regained at least MMR, 78 within 12 months (median 3 months, interquartile range: 2-4 months). Ropeg-IFN was well tolerated (median administered dose of 92 µg, range 3-104), and no new safety signals were observed. Ropeg-IFN maintenance did not improve the probability of sustained TFR after TKI discontinuation.

> **中文摘要：**
> 停用ABL酪氨酸激酶抑制剂（TKI）后获得无治疗缓解（TFR）是慢性髓系白血病（CML）的一个重要治疗目标。干扰素-α（IFN）被认为可促进持久的TFR。3期ENDURE试验（NCT03117816；EUDRA-CT 2016-001030-94）在TKI治疗后获得稳定深度分子学缓解的患者中前瞻性地验证了这一假设。共有203名患者在TKI停药后按1:1随机分配接受ropeginterferon alfa-2b（ropeg-IFN；100µg，每两周皮下注射一次，持续15个月，n=95）或仅观察（n=108）。主要终点为分子学无复发生存期（MRFS），定义为至失去主要分子学反应（MMR）或死亡的时间。中位随访36个月时，ropeg-IFN组的25个月MRFS为56%（95%置信区间（CI），45-66），观察组为59%（95% CI，49-68）（风险比（HR），1.02；95% CI，0.68-1.55；P=0.91）。在83名重启TKI后有分子学数据的患者中，79名（95%）重新获得了至少MMR，其中78名在12个月内获得（中位时间3个月，四分位距：2-4个月）。Ropeg-IFN耐受性良好（中位给药剂量92µg，范围3-104），未观察到新的安全性信号。Ropeg-IFN维持治疗未能提高TKI停药后持续TFR的概率。

### 第二部分 AI 大师评价

本研究旨在通过一项前瞻性随机3期试验，评估在TKI停药后使用Ropeginterferon alfa-2b维持治疗能否提高慢性髓系白血病患者的无治疗缓解率。研究设计严谨，针对已获得稳定深度分子学缓解的患者群体，主要终点设定为分子学无复发生存期。核心发现表明，与单纯观察相比，Ropeginterferon alfa-2b并未显著改善患者的分子学无复发生存，且大部分复发患者在重启TKI后能有效恢复分子学反应。该研究的创新性在于首次在3期试验中系统验证了干扰素在维持TFR中的作用，但其主要局限性在于阴性结果，未能证实先前的假设，提示对于此类深度缓解患者，干扰素维持可能并非必要，未来研究需探索其他策略或更精准的生物标志物来筛选可能获益人群。

---

## 15. 供者年龄与类型权衡的建模：用于采用移植后环磷酰胺预防的异基因造血细胞移植的个性化选择

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41526616)
**期刊：** Leukemia
**PMID：** 41526616
**DOI：** 10.1038/s41375-025-02857-3

### 第一部分 原文与翻译

**英文原标题：** Modeling donor age and type trade-offs for personalized selection in allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide prophylaxis.

> **英文摘要：**
> The prevailing fixed-hierarchy approach to donor selection for allogeneic hematopoietic cell transplantation (HCT) fails to capture critical interactions between donor age and type. We addressed this by analyzing 1713 adult recipients of matched related (MRD), matched unrelated (MUD), or haploidentical donors, receiving post-transplantation cyclophosphamide, using both regularized-Cox and XGBoost machine learning models. Our analysis revealed that the overall, independent association of donor age with survival was modest; however, its importance became pivotal within specific, context-dependent trade-offs. For example, while age-matched MRD and MUD were equivalent, a younger MUD was superior to an older MRD for elderly recipients. The survival advantage of MUD over haploidentical donors was consistent and magnified with increasing recipient age. We identified a non-linear relationship between baseline risk and the benefit of a matched versus a haploidentical donor; with the gain being maximal for intermediate-risk patients but attenuated in the highest-risk stratum. Our framework quantifies the gap that persists even between HLA-favorable haploidentical donors and matched donors. These findings provide a quantitative framework -the principles of which we have made explorable via an interactive web application -for a personalized, risk-adapted approach to donor selection. The clinical utility of this model must be confirmed in future validation studies.

> **中文摘要：**
> 目前异基因造血细胞移植（HCT）供者选择中盛行的固定层级方法，未能捕捉供者年龄与类型之间的关键相互作用。我们通过分析1713例接受移植后环磷酰胺的、来自相合同胞（MRD）、相合无关（MUD）或单倍体相合供者的成年受者，并同时使用正则化Cox和XGBoost机器学习模型，解决了这一问题。我们的分析显示，供者年龄与生存率的总体独立关联性较为有限；然而，在特定的、依赖于具体情境的权衡中，其重要性变得至关重要。例如，虽然年龄匹配的MRD和MUD效果相当，但对于老年受者而言，年轻的MUD优于年长的MRD。MUD相对于单倍体相合供者的生存优势是持续存在的，并且随着受者年龄的增加而放大。我们发现了基线风险与相合供者相对于单倍体相合供者获益之间的非线性关系；获益在中危患者中最大，而在最高危患者中减弱。我们的框架量化了即使在HLA有利的单倍体相合供者与相合供者之间也持续存在的差距。这些发现为一种个性化的、风险适应的供者选择方法提供了一个定量框架——其原理已通过一个交互式网络应用程序可供探索。该模型的临床效用必须在未来的验证研究中得到确认。

### 第二部分 AI 大师评价

本研究旨在挑战并改进异基因造血细胞移植中传统的固定层级供者选择模式。通过整合机器学习模型分析大规模临床数据，研究揭示了供者年龄与类型之间复杂的、情境依赖性的交互作用，并量化了不同供者来源间的生存差距。其核心创新在于构建了一个可交互探索的定量决策框架，为实现个体化、风险适应的供者选择提供了新工具。然而，该模型的有效性仍需前瞻性研究加以验证，且其结论主要适用于采用移植后环磷酰胺预防方案的移植体系。

---

## 16. CHEK2缺失赋予造血干细胞化疗耐药性。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41526615)
**期刊：** Leukemia
**PMID：** 41526615
**DOI：** 10.1038/s41375-025-02850-w

### 第一部分 原文与翻译

**英文原标题：** CHEK2 loss endows chemotherapy resistance to hematopoietic stem cells.

> **英文摘要：**
> Individuals with history of chemo- or radiotherapy frequently exhibit somatic mosaicism in the blood, often involving mutations in genes responsible for DNA damage responses (DDR), such as CHEK2. However, the mechanisms by which CHEK2 mutations promote the expansion of mutant cells following chemo- or radiotherapy remain poorly understood. Here, we demonstrate that loss of CHEK2 confers resistance to chemotherapy in hematopoietic stem and progenitor cells (HSPCs). Through a CRISPR-based screen, we identified CHEK2 as a gene whose loss enhances resistance to cytotoxic chemotherapies. A complementary drug screen revealed that CHEK2-mutant cells are also resistant to DNA hypomethylating agents. Chek2-deficient HSPCs persist in vivo following chemotherapy exposure and exhibit elevated levels of DNA damage compared to wild-type cells. Our findings establish that CHEK2 loss promotes chemoresistance in HSPCs, offering new insights into the role of CHEK2 in therapy-related clonal hematopoiesis observed in cancer patients.

> **中文摘要：**
> 有化疗或放疗史的个体血液中常出现体细胞嵌合现象，通常涉及DNA损伤反应（DDR）相关基因（如CHEK2）的突变。然而，CHEK2突变在化疗或放疗后促进突变细胞扩增的机制仍不清楚。本研究证明，CHEK2缺失会赋予造血干细胞和祖细胞（HSPCs）对化疗的耐药性。通过基于CRISPR的筛选，我们确定CHEK2是一个其缺失能增强对细胞毒性化疗药物耐药性的基因。一项补充药物筛选显示，CHEK2突变细胞对DNA低甲基化药物也具有耐药性。Chek2缺陷的HSPCs在暴露于化疗后能在体内持续存在，并且与野生型细胞相比，表现出更高水平的DNA损伤。我们的研究结果证实，CHEK2缺失促进了HSPCs的化疗耐药性，为理解CHEK2在癌症患者中观察到的治疗相关克隆性造血中的作用提供了新的见解。

### 第二部分 AI 大师评价

本研究旨在阐明CHEK2突变在化疗后驱动突变造血细胞克隆性扩增的机制。研究采用CRISPR筛选和药物筛选相结合的方法，系统性地证明了CHEK2缺失能赋予造血干细胞和祖细胞对多种化疗药物（包括细胞毒性药物和DNA低甲基化剂）的耐药性，并揭示了其与DNA损伤水平升高的关联。其创新性在于首次将CHEK2功能缺失直接与造血干细胞的化疗耐药性及体内持续性联系起来，为解释治疗相关克隆性造血的起源提供了关键机制。局限性在于研究主要基于体外筛选和模型验证，其在复杂人体微环境中的具体调控网络及临床转化意义仍需进一步探索。

---

## 17. 伊美司他治疗较低危骨髓增生异常肿瘤患者的克隆负荷调节作用

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41526614)
**期刊：** Leukemia
**PMID：** 41526614
**DOI：** 10.1038/s41375-025-02831-z

### 第一部分 原文与翻译

**英文原标题：** Modulation of the clonal burden in patients with lower-risk myelodysplastic neoplasms treated with imetelstat.

> **英文摘要：**
> Existing treatments for lower-risk myelodysplastic syndromes/neoplasms (LR-MDS) focus on symptom relief. Until recently, altering the disease course was rarely considered a therapeutic objective. The first-in-class, direct, competitive telomerase inhibitor, imetelstat, demonstrated significantly higher rates of red blood cell (RBC) transfusion independence (TI) versus placebo in patients with non-del(5q), RBC transfusion-dependent LR-MDS who were relapsed/refractory to or ineligible for erythropoiesis-stimulating agents in the Phase 3 IMerge study (NCT02598661). In this exploratory analysis of IMerge, patients treated with imetelstat had greater sustained reductions in variant allele frequency of multiple mutations versus placebo recipients, which was positively associated with RBC-TI duration. Subsequent analyses showed that 70% of patients with a cytogenetic response with imetelstat achieved ≥1-year RBC-TI. Additionally, higher rates of ≥1-year RBC-TI were observed in patients with maximum variant allele frequency reduction of ≥50% in SF3B1 (58% vs. 7%), TET2 (90% vs. 9%), DNMT3A (100% vs. 13%), or ASXL1 (50% vs. 0%) and patients with ≥50% bone marrow ring sideroblast reduction (46% vs. 0%) versus patients who did not. Lastly, 60% of patients with ≥1-year RBC-TI had ≥50% reduction in telomerase activity/human telomerase reverse transcriptase RNA. These results suggest that imetelstat targets clonal progenitor cells and may modify LR-MDS biology.

> **中文摘要：**
> 针对较低危骨髓增生异常综合征/肿瘤（LR-MDS）的现有治疗主要侧重于症状缓解。直到最近，改变疾病进程还很少被视为治疗目标。在III期IMerge研究（NCT02598661）中，对于非del(5q)、红细胞输注依赖且对促红细胞生成药物复发/难治或不适合使用的LR-MDS患者，首创的直接竞争性端粒酶抑制剂伊美司他（imetelstat）相较于安慰剂，显示出显著更高的红细胞输注独立率。在此项针对IMerge研究的探索性分析中，与安慰剂组患者相比，接受伊美司他治疗的患者在多种基因突变的变异等位基因频率上出现了更大程度的持续降低，且这种降低与红细胞输注独立持续时间呈正相关。后续分析显示，在使用伊美司他治疗并获得细胞遗传学缓解的患者中，70%实现了≥1年的红细胞输注独立。此外，与未达到此标准的患者相比，在SF3B1（58% vs. 7%）、TET2（90% vs. 9%）、DNMT3A（100% vs. 13%）或ASXL1（50% vs. 0%）基因突变中最大变异等位基因频率降低≥50%的患者，以及骨髓环形铁粒幼细胞减少≥50%的患者（46% vs. 0%），其≥1年红细胞输注独立的发生率更高。最后，在实现≥1年红细胞输注独立的患者中，60%的患者其端粒酶活性/人端粒酶逆转录酶RNA水平降低了≥50%。这些结果表明，伊美司他靶向克隆祖细胞，并可能改变LR-MDS的疾病生物学特性。

### 第二部分 AI 大师评价

本研究通过探索性分析III期IMerge试验数据，旨在评估伊美司他对较低危MDS患者克隆负荷的调节作用及其与临床获益的关联。核心发现是，伊美司他治疗能持续降低多种基因突变的变异等位基因频率，且这种分子学缓解与更长的红细胞输注独立时间及更高的长期缓解率显著相关，特别是在特定基因突变或骨髓环形铁粒幼细胞减少的患者中。其创新性在于首次在随机对照试验中证实了端粒酶抑制剂可靶向并减少MDS的恶性克隆，为改变疾病进程而非仅缓解症状提供了直接证据。局限性在于这是一项事后探索性分析，其结果需要在前瞻性研究中进一步验证，且对特定生物标志物（如端粒酶活性）的评估样本量有限。

---

## 18. 循环免疫细胞的可解释性炎症图谱

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41526507)
**期刊：** Nature medicine
**PMID：** 41526507
**DOI：** 10.1038/s41591-025-04126-3

### 第一部分 原文与翻译

**英文原标题：** Interpretable inflammation landscape of circulating immune cells.

> **英文摘要：**
> Inflammation is a biological phenomenon beneficial for homeostasis, but it is unfavorable if dysregulated. Although major progress has been made in characterizing inflammation in specific diseases, a global, holistic understanding is still elusive. This is particularly intriguing, considering its function for human health and the potential for modern medicine if fully deciphered. In this study, we leveraged advances in single-cell transcriptomics to delineate inflammatory processes of circulating immune cells during infection, immune-mediated inflammatory diseases and cancer. Our single-cell atlas of more than 6.5 million peripheral blood mononuclear cells from 1,047 patients (56% female, 43% male) and 19 diseases allowed us to learn a comprehensive model of inflammation in circulating immune cells. The atlas expands current knowledge of the biology of inflammation of immune-mediated diseases, acute and chronic inflammatory diseases, infections and solid tumors and lays the foundation to develop a disease分类框架 using unsupervised as well as explainable machine learning. Beyond a disease-centered analysis, we charted altered activity of inflammatory molecules in peripheral blood cells, depicting discriminative inflammation-related genes to further understand mechanisms of inflammation. We present a rich resource for the community and lay the groundwork for learning a classifier for inflammatory diseases, presenting cells in circulation as living biomarkers.

> **中文摘要：**
> 炎症是一种有益于维持稳态的生物学现象，但如果失调则有害。尽管在特定疾病的炎症特征描述方面已取得重大进展，但对其全局性、整体性的理解仍然难以捉摸。考虑到炎症对人类健康的功能以及若能完全破译其对现代医学的潜力，这一点尤其引人入胜。在本研究中，我们利用单细胞转录组学的进展，描绘了感染、免疫介导的炎症性疾病和癌症期间循环免疫细胞的炎症过程。我们基于来自1,047名患者（56%女性，43%男性）和19种疾病的超过650万个外周血单个核细胞的单细胞图谱，使我们能够学习循环免疫细胞中炎症的综合模型。该图谱扩展了当前对免疫介导疾病、急性和慢性炎症性疾病、感染和实体瘤的炎症生物学的认识，并为利用无监督和可解释的机器学习开发疾病分类框架奠定了基础。除了以疾病为中心的分析外，我们绘制了外周血细胞中炎症分子活性的改变图，描绘了具有区分度的炎症相关基因，以进一步理解炎症机制。我们为研究界提供了一个丰富的资源，并为学习炎症性疾病分类器奠定了基础，将循环中的细胞呈现为活体生物标志物。

### 第二部分 AI 大师评价

本研究旨在构建一个全局、可解释的循环免疫细胞炎症图谱。其核心方法是利用大规模单细胞转录组数据（来自19种疾病的超650万个细胞），结合无监督与可解释机器学习，对炎症进行系统性建模。主要发现是扩展了多种疾病背景下炎症的生物学认知，并识别了关键的炎症相关基因与分子活性变化。创新性在于超越了单一疾病视角，提供了一个跨疾病的综合炎症模型，并将循环免疫细胞定位为潜在的活体生物标志物，为疾病分类和机制理解奠定了基础；局限性在于研究主要基于转录组层面，对蛋白功能、细胞间互作等层面的验证与整合有待深入，且临床转化应用仍需前瞻性研究验证。

---

## 19. 靶向SPAK可抑制肝细胞癌进展并逆转免疫耗竭微环境。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41526378)
**期刊：** Nature communications
**PMID：** 41526378
**DOI：** 10.1038/s41467-025-68156-8

### 第一部分 原文与翻译

**英文原标题：** Targeting SPAK suppresses progression and averts an immune exhaustive microenvironment in hepatocellular carcinoma.

> **英文摘要：**
> Protein kinases contribute to hepatocellular carcinoma (HCC) development and immune evasion, posing major challenges for HCC management. Here we show STE20/SPS1-related proline/alanine-rich kinase (SPAK) as a candidate immune exhaustion-associated gene identified through a pooled screen of protein kinases. By integrating bioinformatic analyses, data from patient cohorts, and functional studies in mouse models and cell lines, we demonstrate that elevated expression of SPAK promotes HCC progression, enhances stemness, drives immune exhaustion, and contributes to resistance to targeted therapies. Mechanistically, SPAK phosphorylates GSK3β at Ser9, thereby inhibiting proteasome-mediated degradation of c-Jun and PD-L1. Additionally, we find that DNMT3B-dependent intragenic methylation of SPAK contributes to its high expression in HCC. Notably, the SPAK inhibitor exhibits potent inhibitory effects and synergizes with PD-1 blockade to enhance antitumor efficacy. In summary, these findings establish SPAK as a driver of oncogenesis and immune exhaustion in HCC and highlight dual inhibition as a potential therapeutic strategy.

> **中文摘要：**
> 蛋白激酶参与肝细胞癌（HCC）的发生发展和免疫逃逸，给HCC的治疗带来重大挑战。本研究通过蛋白激酶库筛选，将STE20/SPS1相关的富含脯氨酸/丙氨酸激酶（SPAK）鉴定为一个候选的免疫耗竭相关基因。通过整合生物信息学分析、患者队列数据以及小鼠模型和细胞系的功能研究，我们证明SPAK的高表达会促进HCC进展、增强干细胞特性、驱动免疫耗竭，并导致对靶向治疗的耐药。从机制上讲，SPAK使GSK3β在Ser9位点磷酸化，从而抑制蛋白酶体介导的c-Jun和PD-L1降解。此外，我们发现DNMT3B依赖的SPAK基因内甲基化是其HCC中高表达的原因。值得注意的是，SPAK抑制剂表现出强大的抑制作用，并与PD-1阻断剂协同增强抗肿瘤疗效。总之，这些发现确立了SPAK是HCC中肿瘤发生和免疫耗竭的驱动因子，并强调了双重抑制作为一种潜在的治疗策略。

### 第二部分 AI 大师评价

本研究旨在探索SPAK激酶在肝细胞癌进展与免疫微环境重塑中的作用。研究者综合运用激酶组筛选、多组学分析、临床队列验证及体内外功能实验，系统揭示了SPAK通过磷酸化GSK3β稳定c-Jun和PD-L1、进而驱动肿瘤干细胞特性和免疫耗竭的分子机制，并发现其表达受DNMT3B介导的表观遗传调控。创新性地提出了靶向SPAK可逆转免疫耗竭并与PD-1抑制剂协同增效，为HCC联合治疗提供了新靶点和新策略；但研究主要基于临床前模型，其转化潜力和在异质性人群中的疗效仍需未来临床试验验证。

---

## 20. 二元矿物纳米颗粒实现金属离子血管内递送至肿瘤用于金属免疫治疗。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41526370)
**期刊：** Nature communications
**PMID：** 41526370
**DOI：** 10.1038/s41467-025-68279-y

### 第一部分 原文与翻译

**英文原标题：** Binary mineral nanoparticles enable intravascular delivery of metal ions to tumors for metalloimmunotherapy.

> **英文摘要：**
> Although disruptions in metal ion homeostasis leading to severe cellular damage and regulated cell death are a promising strategy for cancer immunotherapy, challenges in overloading these ions to tumor cells without premature release have limited their therapeutic applications. In this study, we develop binary mineral nanoparticles incorporating both Ca and Na ions to enhance the cytotoxic effects of ion interference in cancer immunotherapy. Engineered using a microfluidic system for uniform size distribution and scalability, these nanoparticles exhibit pH-sensitive ion release. Systemically administered, they preferentially accumulate in tumors, elevating intracellular Ca and Na levels and inducing immunogenic cell death without calcium channel activators or other small-molecule inducers. Our binary mineral nanoparticles significantly enhance antitumor immunity, especially when combined with an immune checkpoint inhibitor, leading to long-term immunity and inhibition of metastasis. This nanotechnology-enabled synergistic delivery of Ca²⁺ and Na⁺ ions represents a promising adjunct to existing metalloimmunotherapy strategies for cancer eradication.

> **中文摘要：**
> 尽管破坏金属离子稳态导致严重细胞损伤和调节性细胞死亡是癌症免疫治疗的一种有前景的策略，但在不过早释放的情况下将这些离子超载至肿瘤细胞的挑战限制了其治疗应用。在本研究中，我们开发了同时包含钙离子和钠离子的二元矿物纳米颗粒，以增强离子干扰在癌症免疫治疗中的细胞毒性效应。这些纳米颗粒采用微流控系统设计，具有均匀的尺寸分布和可扩展性，并表现出pH敏感的离子释放特性。经全身给药后，它们优先在肿瘤中积累，提高细胞内钙和钠水平，并在无需钙通道激活剂或其他小分子诱导剂的情况下诱导免疫原性细胞死亡。我们的二元矿物纳米颗粒显著增强了抗肿瘤免疫，尤其是与免疫检查点抑制剂联用时，可产生长期免疫并抑制转移。这种纳米技术实现的钙离子和钠离子的协同递送，为现有的癌症根除金属免疫治疗策略提供了一个有前景的辅助手段。

### 第二部分 AI 大师评价

本研究旨在解决金属离子在肿瘤免疫治疗中递送效率低和过早释放的难题。其核心创新在于开发了一种兼具钙、钠离子的二元矿物纳米颗粒，利用微流控技术保证均一性，并实现了pH响应性控释。研究发现，该颗粒能特异性在肿瘤部位蓄积，通过协同升高胞内钙钠离子浓度，自主诱导免疫原性细胞死亡，从而显著增强抗肿瘤免疫应答，并与免疫检查点抑制剂产生协同效应，抑制转移。其局限性在于，研究目前主要基于摘要层面，尚需在完整论文中验证其在更广泛肿瘤模型中的普适性、长期生物安全性以及详细的体内代谢动力学。

---

## 21. 用于长期生物标志物监测的植入式皮肤活体传感器显示器

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41526365)
**期刊：** Nature communications
**PMID：** 41526365
**DOI：** 10.1038/s41467-025-67384-2

### 第一部分 原文与翻译

**英文原标题：** Living sensor display implanted on skin for long-term biomarker monitoring.

> **英文摘要：**
> This study introduces an approach to biomarker monitoring through the development of a "Living Sensor Display" implanted on the skin, designed for long-term, continuous tracking of biomarkers, such as inflammatory cytokines. By leveraging the natural high selectivity and sensitivity of keratinocyte stem cells (KSCs) to environmental stimuli, we genetically engineered these cells to express fluorescent proteins in response to specific biomarker signals, specifically TNF-α signalling. This innovation allows for the real-time, non-invasive observation, with the only invasive step being the initial implantation, of biomarker levels directly from the skin surface. We constructed tissue-engineered skin with genetically modified KSCs and transplanted it onto mice, where it successfully engrafted long-term, matured to mimic human skin structures, and responsively indicated the presence of TNF-α through visible fluorescence. This living sensor could repeatedly detect inflammatory responses induced by TNF-α and lipopolysaccharides, highlighting its potential for monitoring various physiological and pathological processes over extended periods. This Living sensor display holds promise for advancing health monitoring and disease prevention strategies by enabling continuous, sensitive, and specific in vivo biomarker tracking.

> **中文摘要：**
> 本研究通过开发一种植入皮肤的“活体传感器显示器”，提出了一种生物标志物监测方法，旨在实现对炎症细胞因子等生物标志物的长期、连续追踪。通过利用角质形成细胞干细胞（KSCs）对环境刺激固有的高选择性和敏感性，我们对这些细胞进行了基因工程改造，使其能够响应特定的生物标志物信号（特别是TNF-α信号）而表达荧光蛋白。这项创新允许直接从皮肤表面对生物标志物水平进行实时、无创观察，唯一的侵入性步骤是初始植入。我们构建了含有基因修饰KSCs的组织工程皮肤，并将其移植到小鼠体内。该移植物成功实现了长期存活，成熟后模拟了人类皮肤结构，并能通过可见荧光响应性地指示TNF-α的存在。这种活体传感器能够重复检测由TNF-α和脂多糖诱导的炎症反应，突显了其在长期监测多种生理和病理过程方面的潜力。这种活体传感器显示器有望通过实现连续、灵敏且特异性的体内生物标志物追踪，来推进健康监测和疾病预防策略。

### 第二部分 AI 大师评价

本研究旨在开发一种新型、可植入的活体生物传感器，用于实现生物标志物的长期、连续、无创监测。其核心创新在于利用基因工程改造的角质形成细胞干细胞作为传感单元，构建组织工程皮肤并移植，将生物标志物信号转化为肉眼可见的荧光显示。研究发现，该“活体传感器显示器”能在小鼠体内长期存活并成熟，并能反复、灵敏地响应TNF-α等炎症信号。该方法将合成生物学与组织工程相结合，为体内实时监测提供了极具前景的平台，但其长期稳定性、免疫原性、信号定量校准及向大型动物或人体转化的可行性仍需未来研究验证。

---

## 22. 缺氧驱动的SELENOP巨噬细胞重塑塑造T细胞动态并促进卵巢癌转移。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41526347)
**期刊：** Nature communications
**PMID：** 41526347
**DOI：** 10.1038/s41467-025-67859-2

### 第一部分 原文与翻译

**英文原标题：** Hypoxia-driven remodeling of SELENOP macrophages shapes T cell dynamics and promotes ovarian cancer metastasis.

> **英文摘要：**
> High-grade serous ovarian cancer (HGSOC) is characterized by extensive transcoelomic dissemination and the accumulation of ascites. However, how site-specific tumor microenvironment (TME) drives progression remains unknown. Here we show the co-occurrence and spatial co-localization of SELENOP macrophages and precursor exhausted CD8 T cells and demonstrate that SELENOP macrophages activate T cells via selenoprotein P in vitro and in vivo. We further identify a dynamic transition in the SELENOP/SPP1 macrophage populations as tumor metastasis, driven by increased hypoxia malignant epithelial cells through VEGFA-EPHB2 signaling. We also reveal that anti-VEGFA intervention controls ovarian tumor growth by increasing SELENOP macrophages and cytotoxicity of CD8 T cells in vivo. Taken together, these findings spotlight the role of tumor-induced TME remodeling in subverting immune-mediated tumor control and thus facilitating HGSOC metastasis in females. Collectively, our results provide a foundation for the development of targeted therapeutic interventions aimed at impeding HGSOC metastatic trajectory.

> **中文摘要：**
> 高级别浆液性卵巢癌（HGSOC）的特征是广泛的经体腔播散和腹水积聚。然而，位点特异性肿瘤微环境（TME）如何驱动进展仍不清楚。在此，我们展示了SELENOP巨噬细胞与前体耗竭CD8 T细胞的共现与空间共定位，并证明SELENOP巨噬细胞在体外和体内通过硒蛋白P激活T细胞。我们进一步发现，随着肿瘤转移，SELENOP/SPP1巨噬细胞群存在动态转变，这是由缺氧恶性上皮细胞通过VEGFA-EPHB2信号驱动的。我们还揭示，抗VEGFA干预通过增加体内SELENOP巨噬细胞和CD8 T细胞的细胞毒性来控制卵巢肿瘤生长。总之，这些发现凸显了肿瘤诱导的TME重塑在颠覆免疫介导的肿瘤控制、从而促进女性HGSOC转移中的作用。总的来说，我们的结果为开发旨在阻碍HGSOC转移进程的靶向治疗干预措施奠定了基础。

### 第二部分 AI 大师评价

本研究旨在阐明高级别浆液性卵巢癌（HGSOC）转移的免疫微环境机制。研究通过多组学空间分析，揭示了缺氧驱动的SELENOP巨噬细胞亚群重塑及其通过硒蛋白P激活前体耗竭CD8 T细胞的独特功能，并发现VEGFA-EPHB2信号轴是驱动这一转变的关键。其创新性在于将缺氧、巨噬细胞表型转换、T细胞功能与肿瘤转移直接联系起来，并验证了抗VEGFA治疗通过调节该轴发挥疗效，为靶向肿瘤微环境的治疗提供了新思路。局限性在于主要基于观察和干预性实验，具体的分子调控网络和临床转化潜力仍需进一步探索。

---

## 23. 图卡替尼联合曲妥珠单抗治疗化疗难治性、HER2阳性、RAS野生型转移性结直肠癌（MOUNTAINEER研究）：最终分析。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41526345)
**期刊：** Nature communications
**PMID：** 41526345
**DOI：** 10.1038/s41467-025-67824-z

### 第一部分 原文与翻译

**英文原标题：** Tucatinib plus trastuzumab for chemotherapy-refractory, HER2 + , RAS wild-type metastatic colorectal cancer (MOUNTAINEER): final analysis.

> **英文摘要：**
> MOUNTAINEER was a multicenter, open-label, phase 2 trial (NCT03043313) that evaluated the efficacy and safety of tucatinib plus trastuzumab, a dual HER2-targeted chemotherapy-free regimen. Patients were included if they had chemotherapy-refractory, HER2+, RAS wild-type unresectable or metastatic colorectal cancer. This final analysis reports updated efficacy and safety after a median follow-up of 32.4 months. Of the 84 patients who received tucatinib plus trastuzumab, the confirmed objective response rate was 39.3%; median duration of response was 15.2 months. Median progression-free survival was 8.1 months and overall survival was 23.9 months. Efficacy was relatively similar across central HER2+ testing methods. No clear association of treatment response with co-occurring biomarker alterations was seen. Few patients discontinued treatment due to adverse events; no treatment-emergent deaths occurred. Tucatinib plus trastuzumab showed clinically meaningful efficacy and favorable safety. Efficacy was observed irrespective of central HER2+ testing methods and in patients with heterogeneous tumor biomarker profiles.

> **中文摘要：**
> MOUNTAINEER是一项多中心、开放标签的2期临床试验（NCT03043313），旨在评估图卡替尼联合曲妥珠单抗（一种双重HER2靶向、不含化疗的方案）的疗效和安全性。患者入组标准为患有化疗难治性、HER2阳性、RAS野生型不可切除或转移性结直肠癌。本次最终分析报告了中位随访32.4个月后的更新疗效和安全性数据。在接受图卡替尼联合曲妥珠单抗治疗的84例患者中，确认的客观缓解率为39.3%；中位缓解持续时间为15.2个月。中位无进展生存期为8.1个月，总生存期为23.9个月。不同中心HER2阳性检测方法之间的疗效相对相似。未观察到治疗反应与共存的生物标志物改变之间存在明确关联。仅有少数患者因不良事件而中止治疗；未发生治疗相关死亡。图卡替尼联合曲妥珠单抗显示出具有临床意义的疗效和良好的安全性。无论采用何种中心HER2阳性检测方法，以及在具有异质性肿瘤生物标志物谱的患者中，均观察到了疗效。

### 第二部分 AI 大师评价

本研究（MOUNTAINEER）的核心目的是评估图卡替尼联合曲妥珠单抗这一无化疗双靶向方案在化疗难治性、HER2阳性、RAS野生型转移性结直肠癌患者中的最终疗效与安全性。通过多中心II期临床试验设计，研究在中位随访超过两年半后证实了该方案持久的抗肿瘤活性（客观缓解率39.3%，中位总生存期23.9个月）和良好的耐受性。其创新性在于为这一特定难治性人群提供了有效的化疗豁免治疗选择，并提示疗效不受中心HER2检测方法或肿瘤生物标志物异质性的显著影响。局限性在于其为单臂II期研究，缺乏与标准治疗或安慰剂的直接对照，且样本量有限，需要更大规模的III期随机试验进一步验证。

---

## 24. 癌症恶病质：分子基础与治疗进展

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41526343)
**期刊：** Signal transduction and targeted therapy
**PMID：** 41526343
**DOI：** 10.1038/s41392-025-02331-7

### 第一部分 原文与翻译

**英文原标题：** Cancer cachexia: molecular basis and therapeutic advances.

> **英文摘要：**
> The dynamic interplay between neoplastic cells and the host has been increasingly recognized as important players in the pathogenesis of cancer cachexia, a syndrome affecting ~50-80% of cancer patients with various incidences of different types of malignancies. Despite its prevalence, a comprehensive understanding of cancer cachexia progression, with a holistic view at the cross-organismal, cellular and molecular levels, remains elusive. In this review, we undertake an in-depth exploration of the relevant target organs and their regulatory roles in cancer cachexia, with a particular focus on macroenvironmental interactions via various organismal crosstalk axes. Moreover, we highlight how systemic metabolic remodeling, a hallmark of cancer cachexia, plays essential roles in modulating the inflammatory responses of immune and stromal cells in the tumor microenvironment (TME). These cellular responses, in turn, disrupt energy metabolism in distant organs and perturb organismal homeostasis by secreting a variety of mediators that activate specific signaling pathways, thereby fostering a vicious cycle that exacerbates cancer cachexia. We comprehensively summarize these complex cellular and molecular networks that constitute reciprocally regulatory dynamics between systemic metabolic reprogramming and inflammatory cascades. Notably, targeting the multifaceted interplay of organismal metabolic remodeling and cancer-associated inflammation holds great promise for clinical translation, as illustrated by a series of innovative therapeutic strategies and ongoing clinical trials aimed at mitigating cachexia in cancer patients.

> **中文摘要：**
> 肿瘤细胞与宿主之间的动态相互作用，已被日益认为是癌症恶病质发病机制中的重要参与者。该综合征影响约50-80%的癌症患者，在不同类型恶性肿瘤中的发病率各异。尽管其普遍存在，但从跨生物体、细胞和分子水平的整体视角，对癌症恶病质进展的全面理解仍然难以捉摸。在本综述中，我们深入探讨了癌症恶病质中相关的靶器官及其调节作用，特别关注通过多种生物体间通讯轴进行的宏观环境相互作用。此外，我们强调了作为癌症恶病质标志的系统性代谢重塑，如何在调节肿瘤微环境（TME）中免疫细胞和基质细胞的炎症反应方面发挥关键作用。这些细胞反应反过来通过分泌多种激活特定信号通路的介质，破坏远处器官的能量代谢并扰乱生物体内稳态，从而形成一个加剧癌症恶病质的恶性循环。我们全面总结了这些构成系统性代谢重编程与炎症级联反应之间相互调节动态的复杂细胞与分子网络。值得注意的是，针对生物体代谢重塑与癌症相关炎症的多层面相互作用，在临床转化方面展现出巨大前景，一系列旨在减轻癌症患者恶病质的创新治疗策略和正在进行的临床试验正说明了这一点。

### 第二部分 AI 大师评价

本综述旨在系统阐述癌症恶病质的分子机制与治疗前景。其方法侧重于从跨生物体、器官、细胞和分子多个层面，剖析肿瘤与宿主间的动态相互作用，特别是通过系统性代谢重塑与炎症反应的恶性循环网络。核心发现是，恶病质并非单一器官病变，而是由肿瘤驱动的、涉及多器官通讯轴和肿瘤微环境炎症的全身性代谢重编程综合征。其创新性在于强调整合“宏观环境”相互作用和系统性代谢-炎症网络的整体视角，为开发靶向多环节的治疗策略提供了理论基础；局限性在于作为综述，其结论主要基于现有研究整合，仍需更多前瞻性临床研究验证这些网络靶点的治疗效能。

---

## 25. 通过靶向CD11b Bregs，抑制RAS/MEK/PI3K通路可增强对CD40激动疗法的反应，从而克服黑色素瘤的PD1耐药性。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41526341)
**期刊：** Nature communications
**PMID：** 41526341
**DOI：** 10.1038/s41467-025-67315-1

### 第一部分 原文与翻译

**英文原标题：** RAS/MEK/PI3K pathway inhibition augments response to CD40 agonism by targeting CD11b Bregs thereby overcoming melanoma PD1-resistance.

> **英文摘要：**
> Development of effective second-line treatment options for patients with BRAFNRAS or BRAFNRAS melanoma resistant to immune checkpoint blockade (ICB) is crucial. While systemic delivery of agonist CD40 (aCD40) plus anti-PD1 (αPD1) showed activity in patients with ICB-resistant melanoma, the objective response rate was modest (15%), in part due to induction of B regulatory cells (Bregs) which suppress CD8 effector T cell responses. We previously reported that RAS/RAF/PI3K-inhibition elevates CD40 expression in melanoma cells and sensitizes tumors to ICB. Here, we show that combined treatment with a RAS/PI3K/AKT-pathway inhibitor rigosertib (RGS), and/or a MEK1/2 inhibitor trametinib (T), plus aCD40, overcomes the ICB resistance of BRAFNRAS and BRAFNRAS melanoma tumors growing in C57BL/6 mice. In addition, overexpression of CD40 in these melanoma cells effectively reverses ICB-resistance and aCD40 + αPD1 treatment induces tumor regression. Mechanistically, RGS + T suppress aCD40-associated CD11bPD-L1 Bregs, promoting CD8 T-cell mediated killing in melanoma. scRNA-Seq analyses confirm CD40-associated CD11b Bregs across cancer types in patients. Our data demonstrate that addition of RAS/PI3K/AKT and MEK inhibitors to aCD40 resolves the issue of aCD40 induction of CD11bPD-L1 Bregs and provides alternative therapeutic options for ICB-resistant BRAFNRAS or BRAFNRAS metastatic melanoma.

> **中文摘要：**
> 为对免疫检查点阻断（ICB）耐药的BRAFNRAS或BRAFNRAS黑色素瘤患者开发有效的二线治疗方案至关重要。虽然全身性给予CD40激动剂（aCD40）联合抗PD1（αPD1）在ICB耐药的黑色素瘤患者中显示出活性，但客观缓解率有限（15%），部分原因是诱导了抑制CD8效应T细胞反应的B调节细胞（Bregs）。我们先前报道，抑制RAS/RAF/PI3K通路可上调黑色素瘤细胞中的CD40表达并使肿瘤对ICB敏感。本文中，我们发现，联合使用RAS/PI3K/AKT通路抑制剂瑞格替尼（RGS）和/或MEK1/2抑制剂曲美替尼（T）与aCD40，能够克服在C57BL/6小鼠中生长的BRAFNRAS和BRAFNRAS黑色素瘤肿瘤的ICB耐药性。此外，在这些黑色素瘤细胞中过表达CD40可有效逆转ICB耐药，并且aCD40 + αPD1治疗可诱导肿瘤消退。机制上，RGS + T抑制了aCD40相关的CD11bPD-L1 Bregs，促进了黑色素瘤中CD8 T细胞介导的杀伤作用。单细胞RNA测序分析证实了患者多种癌症类型中存在CD40相关的CD11b Bregs。我们的数据表明，在aCD40基础上添加RAS/PI3K/AKT和MEK抑制剂，解决了aCD40诱导CD11bPD-L1 Bregs的问题，并为ICB耐药的BRAFNRAS或BRAFNRAS转移性黑色素瘤提供了替代治疗选择。

### 第二部分 AI 大师评价

本研究旨在解决ICB耐药黑色素瘤的治疗难题，核心策略是联合靶向RAS/MEK/PI3K通路与CD40激动疗法。研究发现，通路抑制剂不仅能上调肿瘤CD40表达，更关键的是能抑制aCD40疗法诱导的免疫抑制性CD11bPD-L1 Bregs，从而解除对CD8 T细胞的抑制，增强抗肿瘤免疫。其创新性在于揭示了靶向通路抑制与免疫激动剂联用的新机制，并提供了克服Bregs介导耐药的具体方案。局限性在于研究主要基于小鼠模型，其临床转化效果及在患者中的安全性、最佳组合方案仍需进一步验证。

---

## 26. 骨髓纤维化中的NFκB/IL-6/JAK2/STAT轴是一个关键的、可靶向的脆弱环节，且与JAK2抑制剂治疗耐药相关。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41526340)
**期刊：** Blood cancer journal
**PMID：** 41526340
**DOI：** 10.1038/s41408-025-01447-x

### 第一部分 原文与翻译

**英文原标题：** NFκB/IL-6/JAK2/STAT axis in myelofibrosis is a key vulnerability that is targetable and relevant to JAK2 inhibitor treatment resistance.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要。

### 第二部分 AI 大师评价

本研究聚焦于骨髓纤维化（MF）的分子机制，提出NFκB/IL-6/JAK2/STAT信号轴是疾病进展的关键驱动因素。其核心目的是阐明该信号轴不仅是潜在的治疗靶点，还与临床上JAK2抑制剂耐药现象相关，为克服耐药提供了新的思路。研究创新性地将炎症通路（NFκB/IL-6）与JAK-STAT通路联系起来，构建了更全面的致病模型。然而，由于摘要信息缺失，具体的研究方法、实验数据以及该靶向策略的临床前或临床验证效果尚不明确，这是当前信息下的主要局限性。

---

## 27. VPS18基因突变导致与囊泡稳态紊乱相关的中性粒细胞成熟缺陷。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41526335)
**期刊：** Cell death & disease
**PMID：** 41526335
**DOI：** 10.1038/s41419-025-08338-w

### 第一部分 原文与翻译

**英文原标题：** Mutations in VPS18 lead to a neutrophil maturation defect associated with disturbed vesicle homeostasis.

> **英文摘要：**
> Neutrophils, the first cells to arrive at the site of inflammation, are rather short-lived cells and thus have to be constantly replenished. During neutrophil development, vesicle dynamics need to be fine-tuned and impaired vesicle trafficking has been linked to failure in neutrophil maturation. Here, we characterized the role of VPS18 as a central core component of CORVET & HOPS tethering complexes for neutrophil development. Using CRISPR/Cas9-engineered Hoxb8 cells with heterozygous mutations in Vps18, we found that VPS18 deficiency interfered with neutrophil development due to tethering complex instability. As a result, vesicle dynamics were impaired with a strong increase in LC3B-II and p62 levels, indicating autophagosome accumulation and reduced autophagic flux. With transmission electron microscopy, we verified the increase in autophagosomes and also found irregularly shaped vesicular structures in Vps18 mutants. Subsequently, Vps18 mutant neutrophil progenitors underwent premature apoptosis. We described a novel patient with a heterozygous stop-gain mutation in VPS18 suffering from neutropenia and recurrent infections. To verify our findings in the human system, we used human induced pluripotent stem cells (iPSCs). Upon differentiation into neutrophils, loss of VPS18 resulted in an almost complete absence of iPSC-derived developing neutrophils. Heterozygous VPS18 mutant and patient mutation-harboring iPSCs were characterized by strongly reduced numbers of developing neutrophils. Zebrafish larvae with heterozygous mutations in vps18 were also characterized by significantly reduced neutrophil numbers. This study shows the pivotal impact of VPS18 for adequate vesicle dynamics during neutrophil development which might be relevant in the context of vesicle trafficking during granulopoiesis and congenital neutropenia.

> **中文摘要：**
> 中性粒细胞是最先到达炎症部位的细胞，寿命相当短，因此必须不断补充。在中性粒细胞发育过程中，囊泡动力学需要被精细调控，而受损的囊泡运输与中性粒细胞成熟失败有关。在此，我们阐述了VPS18作为CORVET和HOPS栓系复合体核心组分在中性粒细胞发育中的作用。利用CRISPR/Cas9工程改造的、携带Vps18杂合突变的Hoxb8细胞，我们发现VPS18缺陷因栓系复合体不稳定而干扰中性粒细胞发育。其结果是，囊泡动力学受损，LC3B-II和p62水平显著升高，表明自噬体积累和自噬流减少。通过透射电子显微镜，我们证实了自噬体的增加，并在Vps18突变体中发现形状不规则的囊泡结构。随后，Vps18突变的中性粒细胞祖细胞发生过早凋亡。我们描述了一名携带VPS18杂合性终止获得突变的新患者，其患有中性粒细胞减少症和反复感染。为了在人类系统中验证我们的发现，我们使用了人诱导多能干细胞（iPSCs）。在向中性粒细胞分化时，VPS18的缺失导致iPSC来源的发育中中性粒细胞几乎完全缺失。杂合VPS18突变和携带患者突变的iPSCs的特征是发育中的中性粒细胞数量大幅减少。携带vps18杂合突变的斑马鱼幼虫也表现出中性粒细胞数量显著减少的特征。这项研究揭示了VPS18在中性粒细胞发育过程中对维持适当囊泡动力学的关键影响，这可能与粒细胞生成和先天性中性粒细胞减少症中的囊泡运输过程相关。

### 第二部分 AI 大师评价

本研究核心目的是阐明VPS18基因突变如何通过破坏囊泡稳态导致中性粒细胞成熟缺陷。研究团队综合运用了CRISPR/Cas9基因编辑的细胞模型、患者样本分析、人iPSC分化体系以及斑马鱼模型，多维度验证了VPS18功能缺失对中性粒细胞发育的损害，并揭示了其通过破坏CORVET/HOPS复合体稳定性、损害自噬流并最终引发祖细胞凋亡的分子机制。其创新性在于首次系统地将VPS18、囊泡运输缺陷与人类先天性中性粒细胞减少症联系起来，并建立了从分子机制到临床表型的完整证据链。局限性在于研究主要聚焦于发育阶段，对成熟中性粒细胞的功能（如趋化、吞噬、NETs形成）是否受影响未深入探讨，且患者样本仅为单例，其普遍性有待更多临床数据验证。

---

## 28. 用于快速组装T细胞衔接器靶点的模块化“捕获与激活”平台，助力个性化癌症治疗。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41526331)
**期刊：** Signal transduction and targeted therapy
**PMID：** 41526331
**DOI：** 10.1038/s41392-025-02557-5

### 第一部分 原文与翻译

**英文原标题：** A modular "Catch-and-Play" platform for rapid T-cell engager target assembly for personalised cancer treatment.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要。

### 第二部分 AI 大师评价

本研究提出了一种创新的模块化“捕获与激活”平台，旨在解决个性化癌症治疗中T细胞衔接器（TCE）快速构建的难题。其核心方法是通过模块化设计，实现针对不同肿瘤相关抗原的TCE靶点快速组装，从而适配患者个体化的治疗需求。该平台有望显著缩短TCE疗法的开发周期，提升个性化免疫治疗的可行性。然而，摘要信息缺失，无法评估其具体技术路径、临床前/临床验证数据以及潜在的局限性，如平台效率、脱靶风险或体内稳定性等。

---

## 29. 肉瘤的细胞治疗：现状与未来方向

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41526168)
**期刊：** Journal for immunotherapy of cancer
**PMID：** 41526168
**DOI：** 10.1136/jitc-2025-013396

### 第一部分 原文与翻译

**英文原标题：** Cell therapy in sarcoma: current landscape and future directions.

> **英文摘要：**
> Sarcomas are rare malignancies of mesenchymal origin, characterized by significant biological and clinical heterogeneity. Many subtypes demonstrate limited sensitivity to standard systemic treatments, including immune checkpoint inhibitors. Cell therapy has emerged as a promising strategy, with the potential of durable clinical responses seen with genetically-engineered T-cell receptor T-cell therapies (TCR-T) such as those targeting the cancer-testis antigen MAGE-A4 in synovial sarcoma, leading to the US Food and Drug Administration approval of afamitresgene autoleucel in 2024. This constituted only the second approval of a cell therapy in a solid tumor following lifileucel in melanoma and demonstrated the potential of cell therapies in sarcomas. This review provides the current landscape and growing potential of cell therapies in sarcomas, including TCR-T, chimeric antigen receptor-T cells, tumor-infiltrating lymphocytes, natural killer (NK) cells, and mesenchymal stromal cells. However, the broader application of these therapies is hindered by the lack of targetable sarcoma-restricted immunogenic epitopes, spatiotemporal intratumoral heterogeneity, and a profoundly immunosuppressive tumor microenvironment that impedes effector-cell trafficking, expansion and persistence. While cell therapies hold promise for integration into precision medicine approaches for sarcomas, their successful implementation will require careful evaluation of clinical feasibility, logistical considerations and cost-effectiveness to optimize patient outcomes.

> **中文摘要：**
> 肉瘤是起源于间叶组织的罕见恶性肿瘤，具有显著的生物学和临床异质性。许多亚型对包括免疫检查点抑制剂在内的标准全身治疗敏感性有限。细胞疗法已成为一种有前景的策略，其具有诱导持久临床反应的潜力，这在基因工程T细胞受体T细胞疗法（TCR-T）中可见，例如针对滑膜肉瘤中癌睾抗原MAGE-A4的疗法，这促使美国食品药品监督管理局于2024年批准了afamitresgene autoleucel。这仅是继黑色素瘤中的lifileucel之后，第二种获批用于实体瘤的细胞疗法，并证明了细胞疗法在肉瘤中的潜力。本综述阐述了肉瘤细胞治疗的现状和日益增长的应用潜力，涵盖TCR-T、嵌合抗原受体T细胞、肿瘤浸润淋巴细胞、自然杀伤（NK）细胞和间充质基质细胞。然而，这些疗法的更广泛应用受到以下因素的阻碍：缺乏可靶向的肉瘤特异性免疫原性表位、时空上的瘤内异质性，以及严重抑制效应细胞运输、扩增和持久性的免疫抑制性肿瘤微环境。尽管细胞疗法有望整合到肉瘤的精准医疗方法中，但其成功实施需要仔细评估临床可行性、物流因素和成本效益，以优化患者结局。

### 第二部分 AI 大师评价

本文是一篇关于肉瘤细胞治疗领域的综述。其核心目的是系统梳理包括TCR-T、CAR-T、TIL、NK细胞及间充质基质细胞在内的多种细胞疗法在肉瘤中的研究现状、应用潜力及面临的挑战。文章通过引用2024年FDA批准的首个针对滑膜肉瘤的TCR-T疗法（afamitresgene autoleucel）这一关键案例，有力论证了细胞疗法在实体瘤（特别是肉瘤）中的临床转化潜力与突破性进展。其创新性在于全面整合了当前各类细胞疗法在肉瘤这一复杂、难治性疾病中的最新进展，并前瞻性地指出了将其纳入精准医疗框架的可能性。然而，文章也客观指出了该领域的主要局限性，即靶点稀缺、肿瘤异质性和免疫抑制微环境等生物学障碍，以及临床转化中必须考量的可行性、物流和成本效益等现实问题，为未来研究指明了方向。

---

## 30. 全人源抗B7-H4抗体通过诱导溶酶体依赖性铁死亡逆转PD-1阻断的原发性耐药。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41526167)
**期刊：** Journal for immunotherapy of cancer
**PMID：** 41526167
**DOI：** 10.1136/jitc-2025-013317

### 第一部分 原文与翻译

**英文原标题：** Fully human anti-B7-H4 antibody induces lysosome-dependent ferroptosis to reverse primary resistance to PD-1 blockade.

> **英文摘要：**
> BACKGROUND: Although immune checkpoint inhibitors (ICIs) have significantly improved outcomes for patients with certain cancers, their efficacy is largely confined to "hot" tumors characterized by robust infiltration of tumor-specific CD8 T cells. Conversely, tumors expressing B7-H4 often exhibit an immunologically "cold" tumor microenvironment with poor T cell infiltration, contributing to primary resistance to programmed cell death protein 1 (PD-1) blockade.
> 
> METHODS: We evaluated the association between B7-H4 expression and clinical outcomes in ICI-treated patients using public immunotherapy datasets. The role of B7-H4 in mediating resistance to PD-1 therapy was examined in mouse tumor models. A fully human anti-B7-H4 monoclonal antibody (clone A8) was generated via phage display screening from a non-immunized human single-chain variable fragment library. In vitro assays assessed antibody-induced tumor cell death and immune activation, while in vivo efficacy was tested in MC38-mH4 and SKOV3-hH4 tumor models, as well as human colorectal cancer organoids. Statistical analyses included Student's t-test, one-way analysis of variance, and Kaplan-Meier survival analysis, with p<0.05 considered significant.
> 
> RESULTS: High B7-H4 expression was associated with inferior prognosis in patients receiving ICI therapy. In MC38-mH4 tumors, B7-H4 expression conferred resistance to anti-PD-1 treatment. We identified A8, a novel antibody targeting the IgV-like domain of B7-H4, with cross-reactivity to both human and mouse B7-H4. A8-hIgG1 and its Fab fragment induced dynamin-dependent endocytosis of B7-H4, resulting in lysosomal accumulation, altered lysosomal membrane permeabilization and intracellular acidification, ultimately triggering ferroptosis, a form of immunogenic cell death. A8 binding was enhanced under acidic conditions (pH 5.5), promoting lysosome-dependent degradation of B7-H4. A8-induced ferroptosis enhanced dendritic cell maturation, macrophage phagocytosis, and T cell activation. In vivo, A8 promoted CD8 T cell and HER2 chimeric antigen receptor-T cell infiltration, inhibited tumor growth, and synergized with PD-1 blockade to overcome primary resistance in multiple preclinical models. This immunogenic and lysosome-dependent cell death mechanism was unique to A8 among the anti-B7-H4 antibodies tested.
> 
> CONCLUSIONS: Our study identifies a novel mechanism by which a fully human anti-B7-H4 antibody induces lysosome-dependent immunogenic tumor cell death. These findings support the therapeutic potential of A8 as a single agent or in combination with PD-1 blockade to overcome immune resistance in B7-H4-expressing "cold" tumors.

> **中文摘要：**
> 背景：尽管免疫检查点抑制剂（ICIs）显著改善了部分癌症患者的预后，但其疗效主要局限于以肿瘤特异性CD8 T细胞大量浸润为特征的“热”肿瘤。相反，表达B7-H4的肿瘤通常表现出免疫学上的“冷”肿瘤微环境，T细胞浸润较差，这导致了程序性细胞死亡蛋白1（PD-1）阻断的原发性耐药。
> 
> 方法：我们利用公共免疫治疗数据集评估了B7-H4表达与接受ICI治疗患者临床结局之间的关联。在小鼠肿瘤模型中研究了B7-H4在介导PD-1疗法耐药中的作用。通过噬菌体展示技术从非免疫的人源单链可变区片段库中筛选出一种全人源抗B7-H4单克隆抗体（克隆A8）。体外实验评估了抗体诱导的肿瘤细胞死亡和免疫激活，而体内疗效则在MC38-mH4和SKOV3-hH4肿瘤模型以及人结直肠癌类器官中进行了测试。统计分析包括Student's t检验、单因素方差分析和Kaplan-Meier生存分析，p<0.05被认为具有统计学意义。
> 
> 结果：在接受ICI治疗的患者中，高B7-H4表达与较差的预后相关。在MC38-mH4肿瘤中，B7-H4表达赋予了对抗PD-1治疗的耐药性。我们鉴定出A8，一种靶向B7-H4 IgV样结构域的新型抗体，对人和小鼠B7-H4均具有交叉反应性。A8-hIgG1及其Fab片段诱导了动力蛋白依赖性的B7-H4内吞作用，导致溶酶体聚集、溶酶体膜通透性改变和细胞内酸化，最终触发了铁死亡——一种免疫原性细胞死亡形式。在酸性条件（pH 5.5）下，A8的结合能力增强，促进了B7-H4的溶酶体依赖性降解。A8诱导的铁死亡增强了树突状细胞成熟、巨噬细胞吞噬作用和T细胞活化。在体内，A8促进了CD8 T细胞和HER2嵌合抗原受体T细胞的浸润，抑制了肿瘤生长，并在多个临床前模型中与PD-1阻断协同作用，克服了原发性耐药。在所测试的抗B7-H4抗体中，这种免疫原性且溶酶体依赖性的细胞死亡机制是A8所独有的。
> 
> 结论：我们的研究揭示了一种全人源抗B7-H4抗体诱导溶酶体依赖性免疫原性肿瘤细胞死亡的新机制。这些发现支持了A8作为单药或与PD-1阻断联合使用，以克服表达B7-H4的“冷”肿瘤免疫耐药的治疗潜力。

### 第二部分 AI 大师评价

本研究旨在开发一种新型全人源抗B7-H4抗体（A8），以克服B7-H4阳性“冷”肿瘤对PD-1阻断的原发性耐药。研究通过公共数据分析、小鼠模型验证及抗体筛选，发现A8通过诱导B7-H4内吞和溶酶体依赖性铁死亡，不仅直接杀伤肿瘤细胞，还激活了树突状细胞、巨噬细胞和T细胞，重塑了肿瘤免疫微环境。其核心创新在于首次揭示了抗B7-H4抗体可通过溶酶体-铁死亡轴发挥免疫原性细胞死亡作用，并证明其与PD-1阻断的协同疗效。然而，研究主要基于临床前模型，其人体安全性和有效性尚待临床试验验证，且对铁死亡信号通路的具体调控细节阐述有限。

---

## 31. 细胞外颗粒酶K通过激活F2RL1增强PD-L1的转录与稳定性，从而促进肺腺癌的肿瘤免疫逃逸。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41526166)
**期刊：** Journal for immunotherapy of cancer
**PMID：** 41526166
**DOI：** 10.1136/jitc-2025-013170

### 第一部分 原文与翻译

**英文原标题：** Extracellular granzyme K enhances PD-L1 transcription and stability via F2RL1 activation to facilitate tumor immune evasion in lung adenocarcinoma.

> **英文摘要：**
> BACKGROUND: Granzyme K (GZMK) is a serine protease known for its perforin-dependent cytotoxicity. However, the non-cytotoxic role of GZMK in lung adenocarcinoma (LUAD) remains largely elusive. METHODS: Multiomics datasets were integrated to investigate the clinical relevance of GZMK and its association with programmed death-ligand 1 (PD-L1) in LUAD. Recombinant human GZMK (rhGzmK) was applied in tumor-CD8 T cell co-culture systems, with its effects on PD-L1 expression and CD8 T-cell function evaluated via flow cytometry. Key signaling proteins were analyzed by Western blotting. To evaluate the therapeutic potential of GZMK inhibition, a selective GZMK inhibitor was combined with anti-programmed cell death protein 1 (anti-PD-1) therapy in both C57BL/6 and human peripheral blood mononuclear cells (huPBMC)-reconstituted NVSG humanized mouse models. Finally, multiplex immunofluorescence analysis was conducted on paired pretreatment and post-treatment specimens from a clinical cohort of patients with LUAD receiving immunotherapy to assess the spatial dynamics of GZMK expression in response to treatment. RESULTS: GZMK upregulated PD-L1 expression on tumor cells and enhanced PD-L1/PD-1 binding. Furthermore, GZMK promoted CD8 T-cell dysfunction through the induction of apoptosis, the promotion of CD8 T-cell exhaustion and suppression of proliferation. Mechanistically, cleavage of F2R-like trypsin receptor 1 (F2RL1) by GZMK activated the AKT Serine/Threonine Kinase (AKT) /glycogen synthase kinase-3β/β-catenin and Janus kinase 2/signal transducer and activator of transcription 1 (JAK2/STAT1) pathways, triggering nuclear accumulation of β-catenin and phosphorylated STAT1, which ultimately drove PD-L1 transcription. Additionally, F2RL1 signaling upregulated COPS8, stabilizing PD-L1 through inhibition of its ubiquitin-mediated degradation. In vivo, pharmacological inhibition of GZMK synergized with anti-PD-1 therapy to suppress tumor growth and enhance CD8 T-cell infiltration and function. Clinically, high baseline GZMK expression correlated with an improved response to immunotherapy, and anti-PD-1 treatment modulated the spatial distribution of GZMK within the tumor microenvironment. CONCLUSION: In the absence of perforin, GZMK acquires an immunosuppressive function through F2RL1 activation on tumor cells, which in turn promotes the formation of an immune-suppressive niche. Accordingly, combined targeting of the GZMK/F2RL1 axis and the PD-1/PD-L1 pathway represents a promising synergistic strategy to overcome immune evasion in LUAD.

> **中文摘要：**
> 背景：颗粒酶K是一种丝氨酸蛋白酶，以其穿孔素依赖的细胞毒性而闻名。然而，其在肺腺癌中的非细胞毒性作用在很大程度上仍不清楚。方法：整合多组学数据集以研究GZMK在LUAD中的临床相关性及其与程序性死亡配体1的关联。在肿瘤-CD8 T细胞共培养系统中应用重组人GZMK，并通过流式细胞术评估其对PD-L1表达和CD8 T细胞功能的影响。关键信号蛋白通过蛋白质印迹法进行分析。为评估抑制GZMK的治疗潜力，在C57BL/6小鼠和人外周血单个核细胞重构的NVSG人源化小鼠模型中，将选择性GZMK抑制剂与抗程序性细胞死亡蛋白1疗法联合使用。最后，对接受免疫治疗的LUAD患者临床队列的配对治疗前和治疗后样本进行多重免疫荧光分析，以评估GZMK表达响应治疗的空间动态变化。结果：GZMK上调了肿瘤细胞上的PD-L1表达并增强了PD-L1/PD-1结合。此外，GZMK通过诱导细胞凋亡、促进CD8 T细胞耗竭和抑制增殖来促进CD8 T细胞功能障碍。机制上，GZMK切割F2R样胰蛋白酶受体1激活了AKT丝氨酸/苏氨酸激酶/糖原合酶激酶-3β/β-连环蛋白和Janus激酶2/信号转导与转录激活因子1通路，触发了β-连环蛋白和磷酸化STAT1的核积累，最终驱动了PD-L1的转录。此外，F2RL1信号传导上调了COPS8，通过抑制其泛素介导的降解来稳定PD-L1。在体内，GZMK的药理学抑制与抗PD-1疗法协同作用，抑制了肿瘤生长并增强了CD8 T细胞的浸润和功能。临床上，高基线GZMK表达与更好的免疫治疗反应相关，并且抗PD-1治疗调节了GZMK在肿瘤微环境内的空间分布。结论：在缺乏穿孔素的情况下，GZMK通过激活肿瘤细胞上的F2RL1获得免疫抑制功能，进而促进免疫抑制微环境的形成。因此，联合靶向GZMK/F2RL1轴和PD-1/PD-L1通路是克服LUAD免疫逃逸的一种有前景的协同策略。

### 第二部分 AI 大师评价

本研究旨在揭示颗粒酶K在肺腺癌中不依赖于穿孔素的非细胞毒性免疫抑制功能。通过整合多组学分析、体外共培养、体内人源化小鼠模型及临床样本验证，系统阐明了GZMK通过切割F2RL1受体，激活AKT/β-catenin和JAK2/STAT1信号轴并上调COPS8，从而双重调控PD-L1转录与蛋白稳定性，最终驱动免疫抑制微环境形成的完整机制。其创新性在于发现了GZMK的全新免疫调节角色，并提出了靶向GZMK/F2RL1轴与PD-1/PD-L1阻断的联合治疗新策略。局限性在于，GZMK在肿瘤微环境中细胞来源的异质性及其在不同癌症类型中的普适性仍需进一步探索。

---

## 32. 血清细胞因子可预测接受放化疗联合抗PD-1抗体治疗的食管鳞状细胞癌患者的应答和生存：两项II期临床试验的分析。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41526165)
**期刊：** Journal for immunotherapy of cancer
**PMID：** 41526165
**DOI：** 10.1136/jitc-2025-013065

### 第一部分 原文与翻译

**英文原标题：** Serum cytokines predict response and survival in esophageal squamous cell carcinoma receiving chemoradiotherapy combined with anti-PD-1 antibody: analyses of two phase II clinical trials.

> **英文摘要：**
> PURPOSE: Chemoradiotherapy (CRT) combined with anti-PD-1 for locally advanced esophageal squamous cell carcinoma (ESCC) has shown promising efficacy but lack the predictive biomarkers to identify patients who could benefit from this therapy. The predictive value of serum cytokines in ESCC patients remains unclear. We aimed to identify cytokine-based biomarkers for treatment response and survival in this setting. EXPERIMENTAL DESIGN: Exploratory analyses were conducted on 81 ESCC patients from two phase II trials treated with CRT plus toripalimab, with validation in an independent prospective cohort (n=61). Nineteen serum cytokines were assessed at baseline, during, and post-CRT plus anti-PD-1 antibody. A cytokine-based risk score model (CYTOscore) was constructed. Multi-omics profiling including RNA-seq, WES, and spatial transcriptomics were performed to explore potential differences in tumor microenvironments. RESULTS: Cox analyses identified Interleukin-8 (IL-8), C-C motif chemokine ligand 3 (CCL3), and C-C motif chemokine ligand 4 (CCL4) as potential biomarkers and were used to constructed the CYTOscore. Patients stratified by baseline CYTOscore showed significantly longer OS (HR, 0.31; 95%CI, 0.16-0.62; p= 0.00045) and PFS (HR, 0.33; 95%CI, 0.17-0.62; p= 0.00036) in the low-risk group, which also had higher complete response (CR) rates (66% vs 35%, p=0.014). These finding were next validated in the external cohort, with the low-risk group demonstrating higher CR rates (66% vs 27%, p=0.039) and longer OS (HR 0.30, 95% CI 0.09-0.99, p=0.045). A nomogram incorporating baseline CYTOscore and clinical characteristics showed promising predictive accuracy in 1-, 2-, and 3-year OS (AUC=0.77, 0.78, and 0.76). Multi-omics analysis revealed enriched interferon-γ/α signaling in B cells within low-risk patients. CONCLUSIONS: The CYTOscore based on IL-8, CCL3, and CCL4 effectively predicts treatment response and survival in ESCC patients receiving CRT plus anti-PD-1 antibody.

> **中文摘要：**
> 目的：放化疗联合抗PD-1治疗局部晚期食管鳞状细胞癌已显示出良好的疗效，但缺乏预测性生物标志物来识别可能从此疗法中获益的患者。血清细胞因子在ESCC患者中的预测价值尚不明确。本研究旨在识别基于细胞因子的生物标志物，用于预测该治疗背景下的治疗应答和生存。实验设计：对来自两项II期试验的81例接受放化疗联合特瑞普利单抗治疗的ESCC患者进行了探索性分析，并在一个独立的前瞻性队列（n=61）中进行了验证。在基线、治疗期间及治疗后评估了19种血清细胞因子。构建了一个基于细胞因子的风险评分模型。进行了包括RNA测序、全外显子组测序和空间转录组学在内的多组学分析，以探索肿瘤微环境的潜在差异。结果：Cox分析确定白介素-8、C-C基序趋化因子配体3和C-C基序趋化因子配体4为潜在的生物标志物，并用于构建CYTOscore。根据基线CYTOscore分层的患者中，低风险组的总生存期和无进展生存期显著更长，完全缓解率也更高。这些发现在外部验证队列中得到了验证，低风险组同样显示出更高的完全缓解率和更长的总生存期。整合了基线CYTOscore和临床特征的列线图在预测1年、2年和3年总生存期方面显示出良好的预测准确性。多组学分析揭示了低风险患者B细胞中干扰素-γ/α信号通路富集。结论：基于IL-8、CCL3和CCL4的CYTOscore能有效预测接受放化疗联合抗PD-1抗体治疗的ESCC患者的治疗应答和生存。

### 第二部分 AI 大师评价

本研究旨在解决局部晚期食管鳞癌接受放化疗联合抗PD-1治疗时缺乏有效预测标志物的临床难题。其创新性在于，通过分析两个独立队列的纵向血清细胞因子数据，构建并验证了一个基于IL-8、CCL3和CCL4的简单风险评分模型，该模型在预测完全缓解率和长期生存方面显示出稳健的性能，并整合为临床实用的列线图。多组学分析进一步揭示了低风险患者B细胞中干扰素信号通路的富集，为机制探索提供了线索。局限性在于模型仍需在更大规模、多中心的前瞻性研究中验证，且细胞因子的动态变化及其与肿瘤微环境的因果关系有待深入阐明。

---

## 33. PD1阻断诱导CD8⁺ T细胞表达DKK1促进血脑屏障通透性增加。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41525686)
**期刊：** Cancer discovery
**PMID：** 41525686
**DOI：** 10.1158/2159-8290.CD-25-1222

### 第一部分 原文与翻译

**英文原标题：** PD1 blockade-induced DKK1 expression by CD8+ T cells promotes blood-brain barrier permeabilization.

> **英文摘要：**
> Anti-PD1 therapy benefits a subset of brain metastasis (BrM) patients; however, heterogeneous responses imply an incomplete understanding of the brain-immune ecosystem. To elucidate host-driven determinants of this variability, we performed single-cell RNA sequencing to characterize the brain microenvironment. While anti-PD1 induced robust anti-tumor immune activation, it uniquely, among all ICIs tested, compromised blood-brain barrier (BBB) integrity. This permeabilization was mediated by DKK1-expressing activated CD8⁺ T cells through the induction of β-catenin/TCF and FOXM1 pathways, contributing to endothelial cell destabilization. Depleting plasma-DKK1 restored BBB integrity and reduced experimental BrM formation. Clinically, lung cancer patients receiving anti-PD1 exhibited increased MRI contrast enhancement in the brain, suggestive of BBB perturbations, and increasing plasma DKK1 levels correlated with higher BrM incidence in non-responders. Sequencing anti-PD1 followed by cisplatin improved intracranial cisplatin delivery and therapeutic efficacy in ICI-resistant BrM. These findings identify anti-PD1-induced BBB modulation as a tractable vulnerability in BrM management.

> **中文摘要：**
> 抗PD1疗法使一部分脑转移（BrM）患者获益；然而，异质性反应意味着我们对脑-免疫生态系统的理解尚不完全。为了阐明这种变异性的宿主驱动决定因素，我们进行了单细胞RNA测序以表征脑微环境。尽管抗PD1治疗诱导了强大的抗肿瘤免疫激活，但在所有测试的免疫检查点抑制剂中，它独特地损害了血脑屏障（BBB）的完整性。这种通透性增加是由表达DKK1的活化CD8⁺ T细胞通过诱导β-catenin/TCF和FOXM1通路介导的，导致了内皮细胞的不稳定。清除血浆DKK1可恢复BBB完整性并减少实验性BrM的形成。临床上，接受抗PD1治疗的肺癌患者大脑MRI对比增强增加，提示BBB受到干扰，并且血浆DKK1水平升高与无应答者中较高的BrM发生率相关。序贯使用抗PD1后接顺铂治疗，改善了顺铂在颅内耐药性BrM中的递送和治疗效果。这些发现将抗PD1诱导的BBB调节确定为BrM管理中一个可干预的薄弱环节。

### 第二部分 AI 大师评价

本研究旨在探究抗PD1疗法在脑转移中疗效异质性的机制。通过单细胞RNA测序，研究者发现抗PD1治疗会独特地破坏血脑屏障完整性，其机制是活化的CD8⁺ T细胞表达DKK1，进而激活β-catenin/TCF和FOXM1通路，导致内皮细胞失稳。研究的创新性在于揭示了免疫疗法影响血脑屏障这一非预期的“脱靶”效应，并将其转化为治疗优势，即通过序贯用药增强后续化疗药物的颅内递送。局限性在于临床相关性主要基于观察性数据，且具体信号通路在人体内的作用需进一步验证。

---

## 34. 肝风险评分（LRS）预测无肝病证据退伍军人队列的长期肝脏相关结局。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41525656)
**期刊：** Hepatology (Baltimore, Md.)
**PMID：** 41525656
**DOI：** 10.1097/HEP.0000000000001669

### 第一部分 原文与翻译

**英文原标题：** Liverrisk score (LRS) predicts long-term liver-related outcomes in a cohort of veterans without evidence of liver disease.

> **英文摘要：**
> BACKGROUND AND AIMS: Metabolic dysfunction-associated steatotic liver disease (MASLD) is increasing and disproportionately affects Hispanics. The LiverRisk Score (LRS), a non-invasive stratification tool, could enhance early identification of patients at risk for liver disease; however, it has not been validated in a large U.S. Veteran cohort with sufficient liver-related outcomes.
> 
> APPROACH: We conducted a retrospective cohort study of Veterans Health Administration (VHA) patients from 1999-2023. Individuals with chronic liver disease, viral hepatitis, or missing LRS values were excluded using laboratory and ICD-10 data. Patients were classified into minimal (LRS <6), low (6-<10), medium (10-<15), and high-risk (≥15) categories. Outcomes included liver-related events, mortality, hepatocellular carcinoma (HCC), and C-statistics. Analyses used parametric/non-parametric methods and Cox proportional hazard models with competing risks, adjusting for missing data.
> 
> RESULTS: Among 170,998 Veterans (93% male; median age 60; 63% White), 71%, 26%, 2%, and 0.5% were classified as minimal, low, medium, and high-risk, respectively. Over 13.5 years median follow-up, 15,463 (9%) developed a liver-related event, 6,219 (3.6%) died of liver causes, and 640 (0.5%) developed HCC. C-statistics were 0.61 for events, 0.70 for mortality, and 0.71 for HCC. Accuracy was highest among Hispanic/Latino Veterans (mortality 0.77, 95% CI 0.73-0.81; HCC 0.82, 95% CI 0.75-0.90) versus non-Hispanic Whites (mortality 0.62, 95% CI 0.61-0.62).
> 
> CONCLUSIONS: LRS effectively predicted liver-related events, mortality, and HCC in Veterans. Its integration into clinical alerts and lab reports could support proactive patient care and liver disease prevention.

> **中文摘要：**
> 背景与目的：代谢功能障碍相关脂肪性肝病（MASLD）日益增多，且对西班牙裔人群影响尤为显著。肝风险评分（LRS）作为一种无创分层工具，可增强对肝病风险患者的早期识别；然而，其尚未在拥有充足肝脏相关结局的大型美国退伍军人队列中得到验证。
> 
> 方法：我们对1999年至2023年退伍军人健康管理局（VHA）的患者进行了一项回顾性队列研究。利用实验室和ICD-10数据，排除了患有慢性肝病、病毒性肝炎或LRS值缺失的个体。患者被分为极低风险（LRS <6）、低风险（6-<10）、中风险（10-<15）和高风险（≥15）类别。结局指标包括肝脏相关事件、死亡率、肝细胞癌（HCC）和C统计量。分析采用了参数/非参数方法以及考虑竞争风险的Cox比例风险模型，并对缺失数据进行了调整。
> 
> 结果：在170,998名退伍军人（93%为男性；中位年龄60岁；63%为白人）中，分别有71%、26%、2%和0.5%被归类为极低风险、低风险、中风险和高风险。在中位13.5年的随访期间，15,463人（9%）发生了肝脏相关事件，6,219人（3.6%）死于肝脏原因，640人（0.5%）罹患HCC。C统计量对于事件为0.61，对于死亡率为0.70，对于HCC为0.71。该评分在西班牙裔/拉丁裔退伍军人中的准确性最高（死亡率0.77，95% CI 0.73-0.81；HCC 0.82，95% CI 0.75-0.90），高于非西班牙裔白人（死亡率0.62，95% CI 0.61-0.62）。
> 
> 结论：LRS能有效预测退伍军人的肝脏相关事件、死亡率和HCC。将其整合到临床警报和实验室报告中，可支持主动的患者护理和肝病预防。

### 第二部分 AI 大师评价

本研究旨在验证无创肝风险评分（LRS）在大型美国退伍军人队列中预测长期肝脏相关结局的有效性。通过一项纳入近17万无肝病证据退伍军人的回顾性队列研究，研究者发现LRS能够有效分层预测肝脏相关事件、肝脏相关死亡及肝细胞癌风险，其中在西班牙裔人群中预测准确性尤为突出。研究的创新性在于首次在大型、代表性强的退伍军人群体中验证了LRS的预测价值，并强调了其在特定种族/族裔人群中的潜在优势，为在初级保健或高危人群中实施该工具提供了有力证据。局限性在于摘要未提及对模型进行了哪些具体协变量调整，且C统计量对于事件预测（0.61）仅显示中等区分度，提示其在临床实践中的普适性可能仍需结合其他指标综合判断。

---

## 35. 胆管癌的解剖学亚型：异大于同

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41525598)
**期刊：** Hepatology (Baltimore, Md.)
**PMID：** 41525598
**DOI：** 10.1097/HEP.0000000000001672

### 第一部分 原文与翻译

**英文原标题：** Anatomic subsets of cholangiocarcinoma: More different than alike.

> **英文摘要：**
> Cholangiocarcinoma (CCA) represents a biologically and clinically heterogeneous group of biliary tract malignancies. Growing evidence underscores that the three major anatomic subtypes - intrahepatic (iCCA), perihilar (pCCA), and distal (dCCA) - are distinct tumor entities rather than a single disease. Each subtype differs in embryologic origin, carcinogenesis mechanisms, molecular landscape, and immunogenic profile, all of which contribute to variability in diagnosis, treatment responsiveness and prognosis. The importance of understanding these distinctions is reinforced by the rising global incidence of CCA, highlighting precision medicine approaches based on these subtypes. Recent advances have deepened our insight into subtype-specific risk factors, including chronic biliary diseases and metabolic conditions, while artificial intelligence-driven tools are improving diagnostic accuracy and risk stratification. Surgical innovations now allow for more tailored resections and perioperative care, and therapeutic strategies are increasingly guided by molecular and immune profiling. Emerging strategies for early diagnosis and chemoprevention in high-risk populations further emphasize the significance of recognizing the unique biology of each subtype. In this review, we provide a comprehensive overview of the distinct anatomic subsets of CCA, integrating their molecular and biological foundations with clinical management to inform practice and guide future research.

> **中文摘要：**
> 胆管癌（CCA）代表了一组在生物学和临床上具有异质性的胆道恶性肿瘤。越来越多的证据强调，三个主要的解剖学亚型——肝内胆管癌（iCCA）、肝门部胆管癌（pCCA）和远端胆管癌（dCCA）——是截然不同的肿瘤实体，而非单一疾病。每个亚型在胚胎起源、致癌机制、分子图谱和免疫原性特征上均存在差异，所有这些都导致了其在诊断、治疗反应性和预后方面的变异性。全球CCA发病率的上升强化了理解这些区别的重要性，凸显了基于这些亚型的精准医学方法。最近的进展加深了我们对亚型特异性风险因素（包括慢性胆道疾病和代谢状况）的认识，同时人工智能驱动的工具正在提高诊断准确性和风险分层能力。外科创新现在允许进行更个体化的切除术和围手术期护理，治疗策略也越来越多地受到分子和免疫谱分析的指导。针对高危人群的早期诊断和化学预防的新兴策略，进一步强调了认识每个亚型独特生物学特性的重要意义。在本综述中，我们全面概述了CCA不同的解剖学亚型，将其分子和生物学基础与临床管理相结合，以指导实践并引领未来研究。

### 第二部分 AI 大师评价

本综述的核心目的是系统阐述胆管癌不同解剖学亚型（肝内、肝门部、远端）作为独立疾病实体的生物学与临床差异，并整合最新进展以指导精准诊疗。方法上，文章综合了现有证据，从胚胎起源、分子机制到临床管理进行横向比较，并纳入了人工智能、分子分型等新兴技术应用。其核心发现是强调基于亚型的异质性对诊断、治疗及预后的决定性影响，创新性在于将基础生物学特征与外科、内科及预防策略紧密结合，为个体化医疗提供了清晰框架。局限性在于作为一篇综述，其结论主要基于对现有研究的整合，而非报告新的原始数据，且对于各亚型间具体分子通路的相互作用及更广泛临床验证的需求，仍有待未来研究深入探索。

---

## 36. 药物再利用：瑞美替罗通过MDK/LRP1介导的代谢重编程和免疫抑制机制抑制MASH相关肝细胞癌

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41525571)
**期刊：** Hepatology (Baltimore, Md.)
**PMID：** 41525571
**DOI：** 10.1097/HEP.0000000000001675

### 第一部分 原文与翻译

**英文原标题：** Repurposing resmetirom suppresses MASH-associated hepatocellular carcinoma, with mechanistic implications of MDK/LRP1-mediated metabolic reprogramming and immunosuppression.

> **英文摘要：**
> BACKGROUND AIMS: The mechanisms underlying metabolic dysfunction-associated steatohepatitis (MASH)-associated hepatocellular carcinoma (HCC) are poorly understood, and effective treatments are lacking. This study explored the translational potential of Resmetirom, a clinically approved thyroid hormone receptor-beta (Thrb) agonist and investigated the mechanistic basis of MASH-associated hepatocarcinogenesis. APPROACH RESULTS: Repurposing Resmetirom for MASH-HCC treatment demonstrated significant tumor-suppressive effects across multiple preclinical models. To further investigate its mechanisms, we employed a Western diet plus CCl₄-induced murine MASH-HCC model, complemented by single-cell RNA sequencing (scRNA-seq) analyses of liver and tumor tissues. These analyses revealed active cell-cell communication within the tumor microenvironment, particularly involving hepatic stellate cells (HSCs) and dysplastic hepatocytes (dys-Heps). These cells showed marked upregulation of midkine (MDK), which in human HCC correlated with shorter relapse-free survival, specifically in non-viral, non-alcohol-related cases. In mouse models, MDK facilitated M2-like macrophage polarization via interaction with the receptor LRP1, contributing to disease progression from MASH to fibrosis and eventual HCC. Silencing LRP1 in macrophages abolished MDK-driven M2 polarization and increased cytotoxic cytokine secretion, while LRP1-positive macrophages contributed to T cell exhaustion through the CXCL16-CXCR6 axis. MDK expression negatively correlated with Thrb and lipolytic genes, but positively with lipogenesis genes. Resmetirom treatment not only significantly suppressed tumor growth and reduced steatosis but also decreased MDK expression and increased Thrb levels. Combining Resmetirom and an MDK inhibitor (iMDK) synergistically suppressed tumorigenesis in vivo. CONCLUSIONS: Targeting the MDK/LRP1 axis with Resmetirom offers a promising therapeutic strategy for MASH-associated HCC, addressing both metabolic dysfunction and tumor progression.

> **中文摘要：**
> 背景与目的：代谢功能障碍相关脂肪性肝炎（MASH）相关肝细胞癌（HCC）的机制尚不清楚，且缺乏有效治疗方法。本研究探索了已获批临床的甲状腺激素受体β（Thrb）激动剂瑞美替罗的转化潜力，并研究了MASH相关肝癌发生的机制基础。方法与结果：将瑞美替罗重新用于MASH-HCC治疗，在多种临床前模型中显示出显著的肿瘤抑制效果。为进一步探究其机制，我们采用了西方饮食联合CCl₄诱导的小鼠MASH-HCC模型，并辅以肝脏和肿瘤组织的单细胞RNA测序（scRNA-seq）分析。这些分析揭示了肿瘤微环境内活跃的细胞间通讯，特别是涉及肝星状细胞（HSCs）和异型增生肝细胞（dys-Heps）。这些细胞显示出中期因子（MDK）的显著上调，而在人类HCC中，MDK与较短的无复发生存期相关，特别是在非病毒、非酒精相关的病例中。在小鼠模型中，MDK通过与受体LRP1相互作用，促进了M2样巨噬细胞极化，从而推动疾病从MASH进展为纤维化并最终发展为HCC。在巨噬细胞中沉默LRP1可消除MDK驱动的M2极化并增加细胞毒性细胞因子的分泌，而LRP1阳性巨噬细胞则通过CXCL16-CXCR6轴促进了T细胞耗竭。MDK表达与Thrb和脂肪分解基因呈负相关，但与脂肪生成基因呈正相关。瑞美替罗治疗不仅显著抑制了肿瘤生长并减少了脂肪变性，还降低了MDK表达并提高了Thrb水平。瑞美替罗与MDK抑制剂（iMDK）联合应用在体内协同抑制了肿瘤发生。结论：使用瑞美替罗靶向MDK/LRP1轴，为MASH相关HCC提供了一种有前景的治疗策略，同时针对代谢功能障碍和肿瘤进展。

### 第二部分 AI 大师评价

本研究旨在探索已获批药物瑞美替罗对MASH相关肝癌的治疗潜力及其机制。研究通过整合多种临床前模型、单细胞测序和分子生物学技术，系统揭示了MDK/LRP1信号轴在连接代谢重编程、免疫抑制（特别是M2巨噬细胞极化和T细胞耗竭）与肝癌进展中的核心作用。其创新性在于将代谢调节药物（Thrb激动剂）的作用机制与肿瘤微环境中的关键免疫代谢轴（MDK/LRP1）联系起来，并验证了联合靶向该轴的协同疗效，为MASH-HCC提供了新的联合治疗思路。局限性在于，研究结论主要基于临床前模型，其在人类患者中的有效性和安全性仍需临床试验进一步验证。

---

## 37. 系统治疗与前列腺特异性膜抗原成像时代下的局限性前列腺癌病灶强化放疗

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41525515)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41525515
**DOI：** 10.1200/JCO-25-02107

### 第一部分 原文与翻译

**英文原标题：** Focal Boosting in Localized Prostate Cancer in the Era of Systemic Therapy and Prostate-Specific Membrane Antigen Imaging.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要。

### 第二部分 AI 大师评价

本文聚焦于局限性前列腺癌的精准放疗策略，探讨在前列腺特异性膜抗原（PSMA）成像技术普及和系统治疗（如新型内分泌治疗）广泛应用的新时代背景下，“病灶强化”放疗的应用前景。其核心目的是评估如何利用先进的影像技术识别并靶向肿瘤内更具侵袭性的病灶，从而在提高局部控制率的同时，尽可能减少对正常组织的损伤。这一理念代表了前列腺癌放疗从“均一剂量”向“风险分层剂量”的范式转变，具有显著的临床创新性。然而，其局限性在于，目前尚缺乏长期随访数据来证实这种强化策略在改善患者总生存或无转移生存方面的确切获益，且最佳剂量提升方案和患者选择标准仍需进一步研究明确。

---

## 38. 回复：病理学完全缓解能否作为有效的替代终点？

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41525514)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41525514
**DOI：** 10.1200/JCO-25-02767

### 第一部分 原文与翻译

**英文原标题：** Reply to: Can Pathologic Complete Response Serve as a Valid Surrogate End Point?

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要。

### 第二部分 AI 大师评价

本文是一篇针对“病理学完全缓解（pCR）作为替代终点有效性”讨论的回复性文章。其核心目的在于就pCR作为肿瘤新辅助治疗临床试验替代终点的适用性、验证标准及潜在局限性进行学术回应与探讨。文章形式为评论或回复，而非原始研究，因此不涉及具体研究方法或数据发现。其价值在于参与并推动该重要方法学议题的深入讨论，但受限于体裁，其创新性主要体现在观点阐述与辩论上，而非提供新的实证数据。

---

## 39. 在精准肿瘤学时代，是时候摒弃统一的原发灶不明癌症概念了吗？

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41525513)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41525513
**DOI：** 10.1200/JCO-25-02189

### 第一部分 原文与翻译

**英文原标题：** Is It Time to Retire the Unified Cancer of Unknown Primary Concept in the Precision Oncology Era?

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要。

### 第二部分 AI 大师评价

本文是一篇观点性文章，其核心目的在于挑战并反思在精准肿瘤学背景下，“原发灶不明癌症”作为一个统一疾病概念的临床价值。文章可能通过综述当前分子诊断技术（如基因组学、转录组学）在识别肿瘤起源和治疗靶点方面的进展，论证传统基于病理形态学的“未知原发”分类已显得过时。其创新性在于提出了一个范式转变的倡议，主张根据分子特征而非原发部位来指导治疗，但局限性在于未提供具体的临床研究数据来支持这一观点，且其实践应用可能受限于分子检测的可及性和成本。

---

## 40. 生物学可解释的深度学习衍生的MRI表型揭示肝内胆管癌的淋巴结受累及新辅助治疗反应。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41525512)
**期刊：** Hepatology (Baltimore, Md.)
**PMID：** 41525512
**DOI：** 10.1097/HEP.0000000000001671

### 第一部分 原文与翻译

**英文原标题：** Biologically interpretable deep learning-derived MRI phenotypes reveal lymph node involvement and neoadjuvant therapy response in intrahepatic cholangiocarcinoma.

> **英文摘要：**
> BACKGROUND AIMS: Accurate N-staging of intrahepatic cholangiocarcinoma (iCCA) remains challenging using noninvasive approaches. We aimed to develop a model to refine lymph node (LN) involvement stratification and inform therapeutic consideration. APPROACH AND RESULTS: This study enrolled a discovery cohort (n=682), an internal test cohort from the FU-iCCA (n=204) and an external multicenter cohort (n=88) for model development, and a neoadjuvant therapy (NAT) cohort (n=145) for therapeutic evaluation of the model. A SwinU-CliRad framework was constructed by integrating Swin UNEt TRansformers (SwinU)-based magnetic resonance imaging-derived outputs of LN involvement with clinicoradiological features. Correlations between SwinU outputs and tumor multi-omics profiles were explored. The SwinU-CliRad model achieved area under the curves of 0.932, 0.867, and 0.888 in LN risk stratification, and outperformed radiologist-based assessments by correcting more misclassifications than it introduced across the discovery, internal and external test cohorts (18.8% vs. 7.3%, 18.1% vs. 4.9%, and 17.0% vs. 5.7%), respectively. In the NAT cohort, patients classified as high LN-involved risk by the SwinU-CliRad exhibited lower residual viable tumor rates than those with low LN-involved risk, with higher rates of pathological complete response (12.0% vs. 4.2%) and major pathological response (14.0% vs. 8.4%). SwinU outputs were associated with KRAS mutations, MUC5AC overexpression and the large-duct histological subtype. Single-cell RNA sequencing analysis linked LN involvement to an immune-suppressive stroma tumor microenvironment. CONCLUSION: The SwinU-CliRad model can serve as a biologically interpretable tool for LN risk stratification in iCCA surgical候选人, with high-risk patients identified by the model potentially deriving benefit from NAT.

> **中文摘要：**
> 背景与目的：使用非侵入性方法对肝内胆管癌（iCCA）进行准确的N分期仍然具有挑战性。我们旨在开发一个模型，以优化淋巴结（LN）受累分层并为治疗决策提供信息。方法与结果：本研究纳入了用于模型开发的发现队列（n=682）、来自FU-iCCA的内部测试队列（n=204）和外部多中心队列（n=88），以及用于模型治疗评估的新辅助治疗（NAT）队列（n=145）。通过整合基于Swin UNEt TRansformers（SwinU）的磁共振成像衍生的LN受累输出与临床放射学特征，构建了SwinU-CliRad框架。探索了SwinU输出与肿瘤多组学特征之间的相关性。SwinU-CliRad模型在LN风险分层中获得的曲线下面积分别为0.932、0.867和0.888，并且在发现、内部和外部测试队列中，其纠正的错误分类多于其引入的错误分类（分别为18.8% vs. 7.3%、18.1% vs. 4.9%和17.0% vs. 5.7%），从而优于基于放射科医师的评估。在NAT队列中，被SwinU-CliRad分类为高LN受累风险的患者比低LN受累风险的患者表现出更低的残余存活肿瘤率，同时具有更高的病理完全缓解率（12.0% vs. 4.2%）和主要病理缓解率（14.0% vs. 8.4%）。SwinU输出与KRAS突变、MUC5AC过表达和大胆管组织学亚型相关。单细胞RNA测序分析将LN受累与免疫抑制性间质肿瘤微环境联系起来。结论：SwinU-CliRad模型可作为一种生物学可解释的工具，用于iCCA手术候选者的LN风险分层，模型识别出的高风险患者可能从NAT中获益。

### 第二部分 AI 大师评价

本研究旨在开发一种生物学可解释的深度学习模型（SwinU-CliRad），以解决肝内胆管癌（iCCA）非侵入性N分期的难题。其核心创新在于整合了基于Swin Transformer的MRI影像特征与临床放射学数据，构建了一个在多个独立队列中均优于放射科医师评估的淋巴结风险分层工具。研究发现该模型不仅能准确预测淋巴结受累风险，其影像表型还与特定的分子亚型（如KRAS突变）及免疫抑制微环境相关，并能够识别出可能从新辅助治疗中获益的高风险患者。然而，研究主要基于回顾性队列，且模型在外部验证中的性能略有下降，未来需要前瞻性研究进一步验证其临床实用性和泛化能力。

---

## 41. 回复：系统性治疗与前列腺特异性膜抗原成像时代下局限性前列腺癌的局部剂量提升

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41525511)
**期刊：** Journal of clinical oncology : official journal of the American Society of Clinical Oncology
**PMID：** 41525511
**DOI：** 10.1200/JCO-25-02744

### 第一部分 原文与翻译

**英文原标题：** Reply to: Focal Boosting in Localized Prostate Cancer in the Era of Systemic Therapy and Prostate-Specific Membrane Antigen Imaging.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要。

### 第二部分 AI 大师评价

本文是一篇针对特定议题的回复信，其核心目的是在系统性治疗和PSMA-PET成像技术日益普及的背景下，就局限性前列腺癌放疗中“局部剂量提升”这一策略进行学术讨论。由于缺乏摘要，无法直接获知其具体方法、研究发现或数据支持。此类信件通常旨在澄清观点、回应质疑或深化讨论，其价值在于聚焦前沿争议点，但局限性在于缺乏原创性研究数据，论证深度依赖于所回复的原文及作者的论述逻辑。

---

## 42. Betibeglogene autotemcel基因疗法治疗输血依赖性β-地中海贫血的长期疗效与安全性结果

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41525466)
**期刊：** Blood
**PMID：** 41525466
**DOI：** 10.1182/blood.2025029196

### 第一部分 原文与翻译

**英文原标题：** Long-term efficacy and safety results of betibeglogene autotemcel gene therapy for transfusion-dependent β-thalassemia.

> **英文摘要：**
> Betibeglogene autotemcel (beti-cel) gene therapy for transfusion-dependent β-thalassemia (TDT) involves autologous transplantation of hematopoietic stem and progenitor cells transduced with a modified β-globin gene to produce functional adult hemoglobin (HbAT87Q). Sixty-three participants with TDT (median [range] age: 17 [4-35] years) received beti-cel in phase 1/2 (n = 22) or phase 3 (n = 41) studies and enrolled in the long-term follow-up LTF-303 study (clinicaltrials.gov/NCT02633943; median [range] follow-up: 5.9 [2.9-10.1] years). Manufacturing refinements in phase 3 increased transduction efficiency, resulting in higher drug product vector copy number and HbAT87Q levels, which translated into higher hemoglobin and transfusion independence (TI) rates compared with phase 1/2. TI was achieved by 68.2% (15/22) of phase 1/2 participants (median weighted average Hb during TI, 10.2 g/dL) and 90.2% (37/41) of phase 3 participants (median, 11.2 g/dL) and was sustained through last follow-up. Treatment efficacy was similar across ages and TDT genotypes. Among participants achieving TI, 73% (38/52) had discontinued iron chelation at last follow-up, with no increase in liver iron concentration. Markers of ineffective erythropoiesis, including serum transferrin receptor and erythropoietin, improved with restoration of iron homeostasis. Health-related quality-of-life assessment scores showed durable improvements. No malignancies, insertional oncogenesis, or vector-derived replication-competent lentivirus were reported. These findings establish beti-cel as a durable, one-time therapy that achieves TI, restores iron balance, and improves quality of life, offering a potentially curative treatment option for people with TDT.

> **中文摘要：**
> Betibeglogene autotemcel (beti-cel) 基因疗法治疗输血依赖性β-地中海贫血（TDT）涉及自体移植经修饰β-珠蛋白基因转导的造血干细胞和祖细胞，以产生功能性的成人血红蛋白（HbAT87Q）。63名TDT患者（中位[范围]年龄：17 [4-35] 岁）在1/2期（n = 22）或3期（n = 41）研究中接受了beti-cel治疗，并加入了长期随访LTF-303研究（clinicaltrials.gov/NCT02633943；中位[范围]随访时间：5.9 [2.9-10.1] 年）。3期生产工艺的改进提高了转导效率，导致药物产品的载体拷贝数和HbAT87Q水平更高，从而转化为比1/2期更高的血红蛋白水平和输血独立性（TI）率。1/2期参与者中有68.2%（15/22）实现了TI（TI期间加权平均Hb中位数为10.2 g/dL），3期参与者中有90.2%（37/41）实现了TI（中位数为11.2 g/dL），并且这种独立性持续到最后一次随访。治疗效果在不同年龄和TDT基因型中相似。在实现TI的参与者中，73%（38/52）在最后一次随访时已停止铁螯合治疗，且肝脏铁浓度未增加。无效红细胞生成的标志物，包括血清转铁蛋白受体和促红细胞生成素，随着铁稳态的恢复而改善。健康相关生活质量评估分数显示出持久的改善。未报告恶性肿瘤、插入性肿瘤发生或载体来源的复制型慢病毒。这些研究结果确立了beti-cel作为一种持久的、一次性的疗法，能够实现TI、恢复铁平衡并改善生活质量，为TDT患者提供了一种潜在的治愈性治疗选择。

### 第二部分 AI 大师评价

本研究旨在评估betibeglogene autotemcel基因疗法治疗输血依赖性β-地中海贫血的长期疗效与安全性。通过1/2期和3期临床试验及长期随访，采用自体造血干细胞转导修饰β-珠蛋白基因的方法。核心发现是，经过工艺优化后，3期患者的输血独立性率高达90.2%，且疗效持久，同时恢复了铁稳态并改善了生活质量，未发现相关恶性肿瘤或复制型病毒。其创新性在于证明了该基因疗法作为一次性、潜在治愈性方案的长期有效性和安全性，但研究样本量有限，且缺乏与标准治疗（如造血干细胞移植）的直接长期比较数据。

---

## 43. 区室化的炎症景观与巨噬细胞可塑性调控Tet2+/-介导的克隆性造血。

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41525451)
**期刊：** Blood
**PMID：** 41525451
**DOI：** 10.1182/blood.2024028031

### 第一部分 原文与翻译

**英文原标题：** Compartmentalized inflammatory landscape and macrophage plasticity regulate Tet2+/- mediated clonal hematopoiesis.

> **英文摘要：**
> Clonal hematopoiesis of indeterminate potential (CHIP) is driven by hematopoietic stem cells (HSCs) carrying leukemia-associated mutations that expand in the bone marrow. Several prior studies have revealed that the spatial organization of hematopoietic cells in the bone marrow impacts clonal behaviors. Specifically, leukemic blasts have been found to expand almost exclusively in a subset of marrow cavities that are undergoing active bone remodeling, but whether these cavities also support the expansion of non-malignant mutant clones has never been visualized. Although it is widely appreciated that systemic炎症 promotes the selection of mutant clones, this view has emerged without considering the potential heterogeneity in the inflammatory landscape shaped by local bone remodeling. Leveraging intravital imaging and a murine model of CHIP (Tet2+/-), we demonstrated transcriptional and functional compartmentalization of the marrow microenvironment. Macrophages within non-resorptive cavities are inherently anti-inflammatory, which suppresses disease-initiating Tet2+/- cells while preserving the healthy counterpart. Time-lapse imaging further revealed non-transient association between Tet2+/- clones and CD206+ macrophages. Spatially resolved single-cell transcriptomic profiling and functional assessment revealed that physiological bone remodeling influences CD206+ macrophage plasticity and cytokine secretion which regulate the clonal burden. Additionally, anti-tumor immunity alteration within the microenvironment occurred as early as the formation of initial clones. Suppressing bone remodeling with zoledronate or targeting macrophage-associated niche factors mitigated clonal development. Collectively, our study reveals a previously unrecognized inflammatory landscape shaped by local bone remodeling. The finding presents targetable mechanisms and warrants further studies on the use and precautions of bone-modulating management in clonal blood disorders.

> **中文摘要：**
> 意义未明的克隆性造血（CHIP）是由携带白血病相关突变并在骨髓中扩增的造血干细胞（HSCs）驱动的。先前的多项研究表明，骨髓中造血细胞的空间组织会影响克隆行为。具体而言，已发现白血病原始细胞几乎只在经历活跃骨重塑的一部分骨髓腔中扩增，但这些腔室是否也支持非恶性突变克隆的扩增，此前从未被可视化。尽管人们普遍认识到系统性炎症会促进突变克隆的选择，但这一观点的形成并未考虑由局部骨重塑塑造的炎症景观中潜在的异质性。利用活体成像和CHIP小鼠模型（Tet2+/-），我们证明了骨髓微环境在转录和功能上的区室化。非吸收性腔室内的巨噬细胞本质上是抗炎的，这抑制了疾病起始的Tet2+/-细胞，同时保留了健康的对应细胞。延时成像进一步揭示了Tet2+/-克隆与CD206+巨噬细胞之间的非瞬时性关联。空间分辨的单细胞转录组分析和功能评估表明，生理性骨重塑影响了CD206+巨噬细胞的可塑性和细胞因子分泌，从而调控克隆负荷。此外，微环境内的抗肿瘤免疫改变早在初始克隆形成时即已发生。使用唑来膦酸抑制骨重塑或靶向巨噬细胞相关的生态位因子可减轻克隆发展。总之，我们的研究揭示了一个先前未被认识的、由局部骨重塑塑造的炎症景观。这一发现提供了可靶向的机制，并有必要对骨调节管理在克隆性血液疾病中的使用和注意事项进行进一步研究。

### 第二部分 AI 大师评价

本研究旨在探究骨髓微环境的局部炎症异质性如何调控克隆性造血（CHIP）的发展。研究团队创新性地结合活体成像、Tet2+/-小鼠模型及空间转录组学技术，揭示了骨髓腔室化的炎症景观，并发现CD206+巨噬细胞的可塑性是连接生理性骨重塑与突变克隆扩增的关键枢纽。其核心创新在于将CHIP的驱动因素从“系统性炎症”深化至“局部微环境重塑”，并证实了靶向骨重塑或巨噬细胞生态位可干预克隆进展，为CHIP的预防和治疗提供了新思路。然而，研究主要基于小鼠模型，其结论在人类中的普适性及临床转化潜力仍需进一步验证。

---

## 44. 基于干细胞来源心肌细胞、类器官及小鼠模型描绘免疫检查点抑制剂的非免疫依赖性反应谱

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41525439)
**期刊：** Circulation
**PMID：** 41525439
**DOI：** 10.1161/CIRCULATIONAHA.125.076926

### 第一部分 原文与翻译

**英文原标题：** Profiling Immune-Independent Response to Immune Checkpoint Inhibitors on Stem Cell-Derived Cardiomyocytes, Organoids, and Mouse Models.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 无摘要。

### 第二部分 AI 大师评价

本研究旨在探索免疫检查点抑制剂（ICIs）在心血管系统中的非免疫依赖性直接作用。其核心方法是通过干细胞来源的心肌细胞、心脏类器官以及小鼠模型等多层次研究体系，对ICIs的直接效应进行系统性分析。该研究有望揭示ICIs相关心脏毒性的新机制，为理解其脱靶效应提供了创新视角。然而，由于摘要信息缺失，其具体研究发现、结论的可靠性以及模型与人体病理生理的相关性等关键信息尚无法评估，这是当前信息下的主要局限性。

---

速递结束，祝您工作愉快！